

**M/s SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED**

No.4/3, Plot No. 33, Kurumbapet, Villiyanur,  
Pondicherry, Puducherry – 605009

8<sup>th</sup> Annual Report  
2024-25

BOARD OF DIRECTORS:

Sri. E. Srinivasan

(DIN: 03106171)

Sri. Ajay Babu Narayanam

(DIN: 02929155)

Sri. Srinivas R Gangashettywar

(DIN: 02954408)

Sri. Rakesh Pasupunuri

(DIN: 09628372)

Sri. Jonnalagadda Venkata Nagendraprasad

(DIN: 09628351)

STATUTORY AUDITORS:

M/s. PINNAKA & Co,

Chartered Accountants

H. No. 5-9-279/C/302/1 Mayur Kushal Complex

Gunfoundry, Abids Hyderabad-500 001

REGISTERED OFFICE:

No.4/3, Plot No.33, Kurumbapet, Villiyanur, Pondicherry, Puducherry-605009

## NOTICE TO SHAREHOLDERS

**NOTICE** is hereby given that the 8<sup>th</sup> Annual General Meeting of **Sai Primus Lifebiotech Private Limited** will be held on Tuesday, 30<sup>th</sup> September 2025 at 10.30 AM at the Registered Office of the Company, R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, Pondicherry - 605009, India –to transact the following business:

### ORDINARY BUSINESS:

1. To receive, consider and adopt the Financial Statements of the Company comprising of Balance Sheet of the Company made as at 31<sup>st</sup> March, 2025, the Statement of Profit and Loss & Cash flow Statements for the year ended on that date and a summary of significant accounting policies and other explanatory information together with the Reports of the Board of Directors and Auditors thereon and in this regard, to consider and if thought fit to pass with or without modification(s), the following resolution as Ordinary Resolution:

**“RESOLVED THAT** the audited financial statement of the Company for the financial year ended 31<sup>st</sup> March, 2025 and the reports of the Board of Directors and Auditors thereon, as circulated to the members, be and are hereby considered and adopted.”

### SPECIAL BUSINESS:

2. To ratify the remuneration of the Cost Auditor(s) for the financial years ending 31<sup>st</sup> March 2026 and, in this regard, to pass the following Resolution as an **Ordinary Resolution**:

**“RESOLVED THAT** pursuant to the provisions of Section 148(3) and other applicable provisions of the Companies Act, 2013 (‘the Act’) read with the Rules made thereunder [including any statutory modification(s) or re-enactment(s) thereof for the time being in force], the remuneration payable to M/s. Kandikonda & Associates, Cost Accountants, Membership No. 31775, (Firm Registration No.:101361), appointed by the Board of Directors as Cost Auditors to conduct the audit of the cost accounting records of the Company for the financial year ended March 31, 2026, amounting to ₹65,000/- (Rupees Sixty-Five Thousand only) plus applicable taxes and reimbursement of out-of-pocket expenses incurred in connection with the aforesaid audit, as approved by the Board of Directors of the Company be and is hereby ratified.”

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorised to do all acts, deeds and things and take all such steps as may be necessary, proper or expedient to give effect to this Resolution.”

By Order of the Board  
For Sai Primus Lifebiotech Private Limited



**E.SRINIVASAN**  
Managing Director  
DIN: 03106171

Place: Pondicherry  
Date: 05/09/2025

**NOTES:**

1. A member entitled to attend and vote at the Annual General Meeting (AGM) is entitled to appoint a proxy to attend and vote instead of himself/herself and the proxy need not be a member of the company.
2. The instrument appointing the proxy, in order to be effective, must be deposited at the Company's Registered Office, duly completed and signed, not less than **FORTY-EIGHT HOURS** before the meeting. Proxies submitted on behalf of limited companies, societies, etc., must be supported by appropriate resolutions/authority, as applicable. A person can act as proxy on behalf of Members not exceeding fifty (50) and holding in the aggregate not more than 10% of the total share capital of the Company. In case a proxy is proposed to be appointed by a Member holding more than 10% of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or shareholder.
3. Corporate members intending to send their authorized representatives to attend the meeting are requested to send a letter signed by the competent authority in their organization authorizing their representatives to attend and vote on their behalf at the meeting.
4. In case of joint holders attending the meeting, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote.
5. Members seeking any information with regard to the accounts, are requested to write to the Company at an early date, so as to enable the Management to keep the information ready at the meeting.
6. Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of Companies Act, 2013 and Register of Contracts or arrangements in which directors are interested maintained under Section 189 of the Companies Act, 2013 will be available for inspection by the members at the Annual General Meeting.
7. All documents referred to in the Notice will be available for inspection at the Company's correspondence address during normal business hours on working days up to the date of the AGM.
8. Members/Proxies should bring duly-filled Attendance Slips to attend the meeting.
9. The explanatory statement setting out the material facts pursuant to Section 102 of the Companies Act, 2013, relating to special business to be transacted at the Meeting is annexed.
10. In terms of the requirements of the Secretarial Standard on General Meetings (SS-2) a route map of the venue of the Annual General Meeting is enclosed.



**SAI PRIMUS LIFE**  
BIOTECH PVT. LTD.

**VENUE OF THE 8<sup>th</sup> ANNUAL GENERAL MEETING**



+91 413 2966314



md@splbiotech.com  
www.splbiotech.com  
CIN No: U24304PY2017PTC008147



R.S No. 4/3, Plot No. 33,  
Kurumbapet Industrial Estate,  
Villianur Commune,  
Puducherry - 605 009

**EXPLANATORY STATEMENT U/S 102 OF THE COMPANIES ACT OF 2013**

**ITEM NO. 2: RATIFICATION OF THE REMUNERATION OF THE COST AUDITOR(S)  
FOR THE FINANCIAL YEAR ENDED 31<sup>ST</sup> MARCH, 2026:**

The Board of Directors of the Company, at its meeting held on September 05, 2025, has approved the appointment of M/s. Kandikonda & Associates, Cost Accountants, bearing Membership No. 31775 and Firm Registration No. 101361, as the Cost Auditors of the Company, to conduct the audit of the cost records of the Company for the financial year ending 31st March, 2026.

The Board has also approved the remuneration payable to the Cost Auditors at ₹65,000/- (Rupees Sixty-Five Thousand only), plus applicable taxes and reimbursement of out-of-pocket expenses incurred in connection with the audit.

In terms of the provisions of Section 148(3) of the Companies Act, 2013, read with Rule 14(a)(ii) of the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors, as approved by the Board of Directors, is required to be ratified by the Members of the Company.

Accordingly, the consent of the Members is sought for ratification of the remuneration payable to the Cost Auditors for the financial year ending 31st March, 2026, by passing an Ordinary Resolution as set out at Item No. 3 of the Notice.

The Board of Directors recommends the Ordinary Resolution set out at Item No. 2 of the Notice for approval by the Members.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 2 of the Notice.

By Order of the Board  
For Sai Primus Lifebiotech Private Limited



**E.SRINIVASAN**  
Managing Director  
DIN: 03106171

Place: Pondicherry  
Date: 05/09/2025

**Form No.MGT-11**

**PROXY FORM**

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

<b>CIN</b>	:	U24304PY2017PTC008147
<b>Name of the Company</b>	:	SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED
<b>Registered Office Address</b>	:	R.S.No.4/3, Plot No.33, Kurumbapet, Pondicherry, Puducherry, Pondicherry 605009 India

Name of the Member(s)	
Registered Address	
E-mail Id	Folio No
I/We, being the member(s) of _____ shares of the above-named company. Hereby appoint	
Name:	E-mail Id:
Address:	
Signature, or failing him	
Name:	E-mail Id:
Address:	
Signature:	

As my/ our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 8<sup>th</sup> Annual General Meeting of the Company, to be held on 30<sup>th</sup> September 2025 at 10.30 A.M. at the Registered Office of the Company and at any adjournment thereof in respect of such resolutions as are indicated below:

Sl. No.	Resolution(s)
1	To receive, consider and adopt the Financial Statements of the Company comprising of Balance Sheet of the Company made as at 31 <sup>st</sup> March, 2025, the Statement of Profit and Loss & Cash flow Statements for the year ended on that date and a summary of significant accounting policies and other explanatory information together with the Reports of the Board of Directors and Auditors thereon and in this regard, to consider and if thought fit to pass with or without modification(s), the following resolution as Ordinary Resolution:
2.	To ratify the remuneration of the Cost Auditor(s) for the financial years ending 31 <sup>st</sup> March 2026.

Signed this \_\_\_\_\_ day of \_\_\_\_\_ 2025

Signature of the shareholder Across Revenue Stamp

Affix Revenue Stamp

Signature of Proxy holder

**Note:** This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company not less than 48 hours before the commencement of the Meeting. The proxy need not be a member of the company.

**ATTENDANCE SLIP**

Members or their proxies are requested to present this form for admission, duly signed in accordance with their specimen signatures registered with the Company.

<b>DP ID</b>		<b>Client ID</b>	
<b>Reg. Folio No.</b>		<b>No. of Shares held</b>	

**Name:**

**Address:**

I certify that I am a member / proxy / authorized representative for the member of the Company.

I/We hereby record my/our presence at the 8<sup>th</sup> Annual General Meeting of the Company being held on 30<sup>th</sup> September 2025 at 10.30 A.M. at the Registered Office of the Company.

Please tick in the box

**MEMBER**

**PROXY**

\_\_\_\_\_  
Name of Member / Proxy

\_\_\_\_\_  
Signature of Member / Proxy

## BOARD'S REPORT

Dear Shareholders,  
**Sai Primus Lifebiotech Private Limited**  
Pondicherry.

Your directors have the pleasure of presenting the Eighth (8<sup>th</sup>) Annual Report of the Company together with the Audited Financial Statements for the year ended 31<sup>st</sup> March, 2025.

### **1. FINANCIAL SUMMARY/ HIGHLIGHTS:**

The Company's standalone financial performance for the year under review is as follows:

*(Amount in Lakhs)*

Particulars	FY 2024-25	FY 2023-24
Revenue from operations	7897.80	5638.06
Other Income	44.37	15.07
<b>Total Income</b>	<b>7942.17</b>	<b>5653.12</b>
<b>Total Expenses</b>	<b>6975.33</b>	<b>5159.08</b>
Profit Before extraordinary items and tax	966.84	494.04
Less: Prior period items	0	0
<b>Profit Before Taxation (PBT)</b>	<b>966.84</b>	<b>494.04</b>
Less: Current Income Tax	152.17	86.46
Less: Deferred Tax	123.57	86.17
<b>Profit After Taxation (PAT)</b>	<b>691.09</b>	<b>321.42</b>
<b>Earnings per share (Basic &amp; Diluted) (in Rs.)</b>	<b>230.36</b>	<b>107.14</b>

### **2. RESULTS OF OPERATIONS, BUSINESS OUTLOOK, AND THE STATE OF COMPANIES' AFFAIRS**

The Company is engaged in the business of manufacturing pharmaceutical and nutraceutical. There has been no change in the business of the Company during the financial year ended March 31, 2025.

The Revenue from Operations registered a healthy growth, increasing to ₹7,897.80 lakhs from ₹5,638.06 lakhs in the previous financial year. With Other Income of ₹44.37 lakhs, the Total Income of the Company rose to ₹7,942.17 lakhs as compared to ₹5,653.12 lakhs in the preceding year, reflecting robust top-line expansion.

The Company continued to maintain prudent cost management while supporting business growth. Total Expenses stood at ₹6,975.33 lakhs during the year, as against ₹5,159.08 lakhs in the previous year. As a result, the Profit Before Tax (PBT) more than doubled to ₹966.84 lakhs from ₹494.04 lakhs in the previous financial year, demonstrating improved operating leverage and profitability.

After providing for Current Tax of ₹152.17 lakhs and Deferred Tax of ₹123.57 lakhs, the Company recorded a Net Profit after Tax (PAT) of ₹691.09 lakhs, as compared to ₹321.42 lakhs in the preceding year, underscoring the Company's enhanced earnings capability.

The Earnings Per Share (Basic and Diluted) increased significantly to ₹230.36 from ₹107.14 in the previous year, reflecting improved shareholder value and a stronger financial position.

### 3. ANNUAL RETURN:

The Annual Return of the Company as on 31st March 2025, containing the particulars prescribed under Section 92 of the Companies Act, 2013, has been placed on the Company's website in compliance with the statutory requirements. The web link for the same is provided below.

<https://www.splbiotech.com/investor-center>

### 4. NUMBER OF BOARD MEETINGS CONDUCTED DURING THE YEAR:

The Board met Twelve (12) times during the year under review:

S.No	Date of meeting	Total No of Directors as on date of meeting	No. of Directors Present	
			No. of Directors attended	% of Attendance
1.	05-04-2024	5	5	100%
2.	04-07-2024	5	5	100%
3.	23-07-2024	5	5	100%
4.	05-09-2024	5	5	100%
5.	09-09-2024	5	5	100%
6.	14-09-2024	5	5	100%
7.	20-09-2024	3	3	100%
8.	21-10-2024	5	5	100%
9.	08-11-2024	5	5	100%
10.	02-01-2025	5	5	100%
11.	29-03-2025	5	5	100%

### 5. DETAILS IN RESPECT OF FRAUDS REPORTED BY THE AUDITORS

The Statutory Auditors of your Company have not identified any frauds under Sub-Section 12 of Section 143 of the Companies Act, 2013.

### 6. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORTS:

There are no qualifications, reservations or adverse remarks made by the Auditors in their report; hence there is no requirement for any explanation or comments from the Directors of your Company.

Further, the shares of your Company are neither listed in any of the stock exchanges nor your Company falls under the category of other class of Companies prescribed under Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with Section 204 of the Companies Act, 2013, hence the requirement for a secretarial audit & report from a practicing company secretary does not arise.

**7. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:**

There have been no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of this report, which forms part of this report.

**8. DETAILS OF CHANGE IN DIRECTORS OR KEY MANAGERIAL PERSONNEL**

During the financial year under review, there was a change in the composition of the Board. The Members of the Board consisted of the following Directors during the period under review:

Name of the Director	DIN Number	Designation	Date of Appointment	Date of Cessation
Srinivasan,	03106171	Managing Director	24-03-2017	-
Ajay Babu Narayanam,	02929155	Director	24-03-2017	-
Srinivas Gangashettywar,	02954408	Director	24-03-2017	-
Jonnalagadda Sreedevi	02934051	Director	24-03-2017	14-09-2024
Swapna P	02929202	Director	24-03-2017	14-09-2024
Jonnalagadda Venkata Nagendraprasad	09628351	Director	14-09-2024	19-09-2024
Rakesh Pasupunuri	09628372	Director	14-09-2024	19-09-2024
Jonnalagadda Venkata Nagendraprasad,	09628351	Additional Director	21-10-2024	-
Rakesh Pasupunuri	09628372	Additional Director	21-10-2024	-
Jonnalagadda Venkata Nagendraprasad,	09628351	Director	31-10-2024	-
Rakesh Pasupunuri	09628372	Director	31-10-2024	-

The Board wishes to inform you that the Directors are not disqualified under Section 164 of the Companies Act, 2013 as per the Declaration given by the Directors at the first meeting of the Board of Directors of the Company for the financial year 2024-25.

**9. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNAL:**

Your company has not received any significant material orders passed by the regulators or courts or tribunals.

**10. PARTICULARS OF CONTRACTS OR ARRANGEMENTS ENTERED INTO WITH RELATED PARTIES**

The Company has entered into related party transactions during the financial year under review, and the same have been disclosed in the AOC-2 annexed as Annexure-I to this report. Also, suitable disclosure as required by the Accounting Standards (AS18) has been made in the notes to the Financial Statements.

## **11. COMPLIANCE OF SECRETARIAL STANDARDS**

The Company is in compliance with the applicable Secretarial Standards i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively issued by the Institute of Company Secretaries of India ('ICSI') and approved by the Central Government under Section 118 (10) of the Act for the Financial Year ended 2024-25.

## **12. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013:**

The Company has not provided any loans or guarantees nor made any investments within the meaning of Section 186 during the financial year under review. The Company has granted advances to employees and suppliers in the ordinary course of business, which do not attract the provisions of the said section except as below:

<b>Name of the party</b>	<b>Nature of Transaction</b>	<b>Amount (in Lakhs)</b>
Lifecare Formulations Private Limited	Trade Advance Given	66.55

## **13. TRANSFER TO RESERVES:**

The Company incurred a profit during the year under review and transferred the entire profit of Rs. 691.09 lakhs to the surplus in the profit and loss account as of 31<sup>st</sup> March 2025. Suitable disclosure has been made in Note 4 in the financial statements.

## **14. DIVIDEND:**

Though the Company had incurred profit during the year under review, to conserve resources for the future, the Board have not recommended a dividend for the year ended 31<sup>st</sup> March 2025.

## **15. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO**

The details of the conservation of Energy, Technology, Absorption, Foreign Exchange Earnings and Outgo are as under:

### **a. CONSERVATION OF ENERGY:**

The Steps taken for conservation of Energy:	Considering the nature of pharmaceutical and nutraceutical manufacturing operations, the Company has implemented energy-
The Steps taken for utilizing alternate sources of energy:	

<p>The Capital investment on energy conservation equipment:</p>	<p>efficient operational practices, including optimal utilisation of production machinery, preventive and predictive maintenance schedules, batch-wise production planning to minimise energy losses, and regular monitoring of power consumption across manufacturing and utility areas.</p> <p>During the financial year under review, the Company did not utilise alternate sources of energy, as the existing power infrastructure adequately met operational requirements.</p> <p>No separate capital investment was made in energy conservation equipment during the year under review, as energy efficiency initiatives were integrated into routine operational and maintenance practices.</p>
---	--

**b. TECHNOLOGY ABSORPTION:**

(i)	<p>the effort made towards technology absorption</p>	<p>The Company continues to place strong emphasis on adoption of modern pharmaceutical manufacturing technologies, validated production processes, quality control systems, and compliance-driven operational practices. Continuous upgradation of manufacturing processes, quality testing methodologies, and documentation systems has been undertaken in line with evolving regulatory and customer requirements.</p>
(ii)	<p>the benefits derived like product improvement, cost reduction, product development or import substitution</p>	<p>The technological initiatives have resulted in improved product quality and consistency, enhanced process reliability, better compliance with international regulatory standards, reduced process deviations, and improved operational efficiency, thereby strengthening customer confidence and supporting sustainable growth.</p>

(iii)	in case of imported technology (imported during the last three years reckoned from the beginning of the financial year) (a) the details of technology imported (b) the year of import; (c) whether the technology been fully absorbed (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof	The Company has not imported any technology during the last three financial years.
(iv)	the expenditure incurred on Research and Development	Not Applicable.

**c. FOREIGN EXCHANGE EARNINGS AND OUTGO:**

(Amount in Lakhs)

Particulars	For the year ended 31.03.2025	For the year ended 31.03.2024
Foreign Exchange earnings	1395.27	26.94
Foreign Exchange outgo	58.03	-

**16. STATEMENT INDICATING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY:**

The Board of Directors has devised and implemented a Risk Management Policy for the Company. The Board is responsible for identifying, evaluating, and managing all significant risks that may impact the Company's business, operations, and financial performance. The Risk Management Policy acts as an enabler of growth by providing a structured framework for identifying potential risks, assessing their impact, and monitoring them on a continuous basis. The policy facilitates the timely identification of strategic, operational, financial, and compliance-related risks and enables management to undertake appropriate mitigation measures.

The Board periodically reviews the effectiveness of the Risk Management Policy and is of the opinion that the policy has been implemented effectively and is adequate to address the risks faced by the Company.

**17. CONSTITUTION OF INTERNAL COMPLAINTS COMMITTEE UNDER THE SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE:**

The Company has zero tolerance for sexual harassment at workplace and has a mechanism in place for prevention, prohibition, and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. The Company is committed to providing equal opportunities without regard to race, caste, sex, religion, colour, nationality, disability, etc. All employees are treated with dignity with a view to maintaining a work environment free of sexual harassment, whether physical, verbal or psychological. All employees (permanent, contractual, temporary, trainees) are covered.

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013.

An Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment at workplace. During the year under review, the Company has not received any complaints on sexual harassment and hence there are no complaints pending as on the end of the Financial Year 2024-25 on sexual harassment.

The following is a summary of sexual harassment complaints received and disposed of during the Financial Year 2024-25:

(a)	number of complaints of sexual harassment received in the year;	Nil
(b)	number of complaints disposed off during the year;	Nil
(c)	number of cases pending for more than ninety days	Nil

**18. NAMES OF COMPANIES WHICH HAVE BECOME OR CEASED TO BE SUBSIDIARIES/ ASSOCIATES/ JOINT VENTURES:**

The Company does not have any subsidiaries / Associates or joint ventures during the financial year under review.

No company has become or ceased to be a subsidiary, Associate, or joint venture of the Company during the financial year under review.

**19. DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS IN FINANCIAL STATEMENTS**

The Management is responsible for establishing & maintaining internal controls for financial reporting. The Auditors' report on internal financial control stated that the systems are commensurate with the nature of its business size and the Complexity of the Operations.

**20. STATUTORY AUDITORS**

Pursuant to Section 139 of the Companies Act, 2013 M/s. Pinnaka & Co., Chartered Accountants (Firm Registration No. 008813S), Hyderabad, as the Statutory Auditors of the Company for a term of five (5) consecutive years, was appointed at the 7<sup>th</sup> Annual General Meeting for a period of 5 years from the Conclusion of the 12<sup>th</sup> Annual General Meeting.

Further, in accordance with the latest amendments in the Companies Act, 2013, the requirement of ratifying the appointment of Statutory Auditors at every Annual General Meeting has been omitted. Hence, no ratification by the shareholders is required at every Annual General Meeting for the appointment of Statutory Auditors.

**21. DIRECTORS' RESPONSIBILITY STATEMENT:**

In accordance with the provisions of Section 134(5) of the Companies Act, 2013, your directors hereby confirm that: -

- a. in the preparation of the annual accounts for the financial year ended 31<sup>st</sup> March 2025, the applicable accounting standards had been followed and there are no material departures in adoption of these standards;
- b. the Directors had selected such accounting policies and applied them consistently and made

judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for the period ended on that date;

- c. the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d. the Directors had prepared the annual accounts on a going concern basis; and
- e. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## **22. DEPOSITS:**

The company has not accepted any deposits under Section 73 of the Companies Act, 2013 during the financial year under review. However, the company has accepted loans from directors/relatives of directors during the financial year, as mentioned below:

*(Amount in Lakhs)*

<b>Name of Director</b>	<b>Loan taken during the year</b>	<b>Loan remaining at the end of the year</b>
Srinivasan	-	138.55
Ajay Babu narayanam	-	121.62
Swapna P	-	121.50
Jonnalagadda Sreedevi	-	121.50
Srinivas Gangashettywar	-	121.50
	-	-
Rakesh Pasupunuri		
Jonnalagadda Venkata Nagendraprasad	-	-

## **23. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES:**

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within the purview of Section 135(1) of the Companies Act, 2013 for the financial year 31<sup>st</sup> March, 2025.

However, owing to the increase in the Company's net profits exceeding ₹ 5 crore for the financial year ended 31 March 2025, the Company now falls within the threshold prescribed under Section 135 of the Companies Act, 2013. Accordingly, the CSR provisions shall become applicable from the financial year 2025-26, and the Company shall comply with the requirements of the constitution of the CSR framework and expenditure of the prescribed CSR amount in accordance with the applicable provisions and rules made thereunder. The Board shall take necessary steps for the constitution of the CSR Committee if required and the formulation of the CSR Policy in compliance with the Act.

**24. DISCLOSURE WITH REGARD TO MAINTENANCE OF COST AUDIT:**

The Company is required to maintain cost records in respect of its applicable products. Accordingly, the Company has made and maintained proper cost records as prescribed under the said provisions for the financial year under review.

The cost audit for the financial year has been carried out in compliance with the applicable provisions of the Act and the rules made thereunder by M/s. Kandikonda & Associates, Cost Accountants, a proprietorship firm bearing Firm Registration No. 101361. The cost audit report has been signed by CMA K. Sadaiah, holding Membership No. 31775.

The Board confirms that the cost audit was conducted in accordance with statutory requirements and that the Company has complied with all applicable provisions relating to the maintenance of cost records and cost audit.

**25. SECRETARIAL AUDIT**

The provisions relating to the submission of the Secretarial Audit Report are not applicable to the Company

**26. DETAILS OF THE APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE FINANCIAL YEAR:**

The Company has not made any application or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 during the year under review.

**27. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:**

During the year under review, the Company has availed loan and credit facilities from banks and/or other financial institutions in the ordinary course of business to meet its working capital and business requirements.

As on March 31, 2025, the total borrowings of the Company amounted to ₹ 1,874.56 Lakhs, comprising long-term borrowings of ₹ 1,064.81 Lakhs and short-term borrowings of ₹ 809.75 Lakhs. The total borrowings were further classified into secured borrowings of ₹ 1,249.88 Lakhs and unsecured borrowings of ₹ 624.67 Lakhs. The secured borrowings are secured by a first and exclusive hypothecation charge on the entire current assets of the Company, both present and future, a first and exclusive hypothecation charge on the machinery purchased out of bank finance, and hypothecation of the Company's motor vehicle, as applicable.

The Company has not entered into any one-time settlement with any bank or financial institution. There were no defaults in repayment of principal or interest on such borrowings during the year under review. All borrowings have been utilised for the purposes for which they were obtained and are in compliance with applicable laws and approvals.

**28. MATERNITY BENEFIT:**

Pursuant to Rule 8(5)(xiii) of the Companies (Accounts) Rules, 2014, as amended vide the Companies (Accounts) Second Amendment Rules, 2025, the Board confirms that the Company has complied with the applicable provisions of the Maternity Benefit Act, 1961. The Company provides all eligible women employees with maternity leave, nursing breaks, and such other benefits as mandated under the Act.

**29. STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS:**

The Company is not required to comply with the provisions of Section 149(4) read with Rule 4 of Companies (Appointment and Qualification of Director) rules, 2014 pertaining to the appointment of Independent Directors as your company does not fall within purview of Section and hence your company is not required to appoint Independent Directors.

**30. COMPANY'S POLICY RELATING TO DIRECTORS' APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES:**

The provisions of Section 178(1) relating to constitution of Nomination & Remuneration Committee are not applicable to the Company hence the Company has not devised any policy relating to appointment of Directors, payment of managerial remuneration, Director's qualifications, positive attributes, independence of Directors and other related matters as provided under Section 178(3) of the Companies Act, 2013.

**31. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION & PROTECTION FUND:**

The provisions of Section 125(2) of the Companies Act, 2013 do not apply as there was no dividend declared.

**32. CHANGE(S) IN THE NATURE OF BUSINESS, IF ANY:**

There is no change in the nature of business carried on by the Company.

**33. DECLARATION REGARDING INTEGRITY, EXPERTISE AND PROFICIENCY OF INDEPENDENT DIRECTORS:**

Pursuant to Section 149(8) of the Companies Act, 2013 read with Schedule IV (Code for Independent Directors), the Board is required to satisfy itself regarding the integrity, expertise, experience and proficiency of the Independent Directors appointed during the year.

During the year under review, no Independent Directors were appointed to the Board. Accordingly, the requirement of the Board satisfying itself regarding the integrity, expertise, experience and proficiency of Independent Directors under the above provisions is not applicable.

**34. DISCLOSURE OF THE COMPOSITION OF THE AUDIT COMMITTEE AND PROVIDING A VIGIL MECHANISM**

The provisions of Section 177 of the Companies Act, 2013 read with Rule 6 and 7 of the Companies (Meetings of Board and its Powers) Rules, 2014 is not applicable to the Company.

### 35. SHARE CAPITAL:

As on 31<sup>st</sup> March 2025, the Authorized Share Capital of the Company stood at Rs. 2,00,00,000/- divided into 20,00,000 Equity Shares of ₹10/. The issued and paid-up Share Capital of the Company stood at Rs. 30,00,000/- divided into 3,00,000 Equity Shares of Rs.10/- each.

- The Company has not issued Equity shares during the year under review.
- The Company has not issued equity shares with differential rights as to dividend, voting or otherwise.
- The Company has not bought back any of its securities during the year under review.
- The Company has not issued any Sweat Equity Shares during the year under review.
- No Bonus Shares were issued during the year under review.
- The Company has not provided any Stock Option Scheme to the employees.
- There were no Shares having voting rights not exercised directly by the employees and for the purchase of which or subscription to which a loan was given by the Company.
- As on 31<sup>st</sup> March 2025, none of the Directors of the Company held instruments convertible into equity shares of the Company.

### 36. PARTICULARS OF EMPLOYEES

There are no employees in the Company during the period under review whose remuneration exceeds the limit as stated in Rule 5(2) of the Companies (*Appointment and Remuneration of Managerial Personnel*) Rules, 2014 and hence the provision of details is not applicable.

### 37. DEMATERIALIZATION OF SHARES

During the year under review, the Company had entered into tripartite agreements for dematerialization of equity shares with Purva Shareregistry India Private Limited, National Securities Depository Limited and Central Depository Services (India) Limited. As on the date of the Report, company shares are dematerialised. The Company ISIN No. is INE1UZ601010.

### 38. BUSINESS LOCATIONS

As of March 31, 2025, the company has its place of business in the following location;

<b>Registered Office &amp; Manufacturing Facility</b>	R.S.No.4/3, Plot No.33, Kurumbapet, Pondicherry. Puducherry, Pondicherry 605009 India
<b>Address at which the books of account are to be maintained</b>	Plot No 4625 Old 55 New Door No 6 W Block, 3rd main road 4th Floor Flat No 4A, Anna Nagar (Chennai), Chennai Egmore Nungambakkam, Tamil Nadu 600040 India.

### 39. DESIGNATED PERSON


Mr. Srinivasan, DIN: 03106171, Managing Director of the Company, has been designated as the 'Designated Person' for the purpose of compliance with the provisions of Section 89 of the Companies Act, 2013 read with Rule 9 of the Companies (Management and Administration) Rules, 2014 relating to declaration of beneficial interest in shares.

#### **40. ACKNOWLEDGEMENT**


Your Board of Directors wish to place on record their appreciation to the customers, shareholders, government departments, banks and suppliers for their continued co-operation and support. The support of Bankers has also been invaluable to the Company's performance, and your directors take this opportunity to appreciate it deeply.

Your directors also take this opportunity to acknowledge the dedicated efforts of the staff for their contribution to the success achieved by the company.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF  
SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED**



**AJAY BABU NARAYANAM**  
DIRECTOR  
DIN: 02929155



**SRINIVASAN**  
MANAGING DIRECTOR  
DIN: 03106171

**PLACE: PONDICHERRY**  
**DATE: 05/09/2025**

**ANNEXURE - I**  
**Form No. MGT-9 -EXTRACT OF ANNUAL RETURN**  
**(as on the financial year ended on 31<sup>st</sup> March, 2024)**

*[Pursuant to section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]*

**I. REGISTRATION AND OTHER DETAILS:**

S.NO	PARTICULARS	DETAILS
1	CIN	U24304PY2017PLC008147
2	Registration date	24 <sup>th</sup> March, 2017
3	Name of the Company	<b>Sai Primus Lifebiotech Private Limited</b>
4	Category/ Sub-category of the Company	Company Limited by Shares / Non-Government Company
5	Address of the Registered Office	R.S.No.4/3, Plot No.33, Kurumbapet, Pondicherry, India, 605009.
6	Contact details:	Mr. E.Srinivasan, Director
7	Whether Listed Company-Yes/No	No
8	Name, Address and Contact details of Registrar and Transfer Agent, if any:	Purva Sharegistry India Private Limited Unit no. 9, Shiv Shakti Ind. Estt J.R. Boricha Marg, Lower Parel (E) Mumbai 400 011

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY**

All the business activities contributing 10% or more of the total turnover of the Company shall be stated:

SI. NO.	NAME AND DESCRIPTION OF MAIN PRODUCTS/ SERVICES	NIC CODE OF THE PRODUCT/ SERVICE	% TO TOTAL TURNOVER OF THE COMPANY
1	Manufacturing of Drugs & medicines	24232	100.00%

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES**

S. NO	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ ASSOCIATE	% OF SHARES HELD	SECTION
1		---			

**IV. SHARE HOLDING PATTERN (EQUITY SHARE CAPITAL BREAKUP AS PERCENTAGE OF TOTAL EQUITY):**

**I. CATEGORY-WISE SHARE HOLDING:**

CATEGORY OF SHAREHOLDERS	No. of shares held at the beginning of the year				No. of shares held at the end of the Year				% change during the year
	Demat	Physical	Total	% of total shares	Demat	Physical	Total	% of total shares	
<b>A. PROMOTERS</b>									
Indian									
Individual	0	3,00,000	3,00,000	100.00	0	2,60,100	2,60,100	86.70	0
HUF	0	0	0	0	0	0	0	0	0
Central Govt. State Govt.(s)	0	0	0	0	0	0	0	0	0
Bodies Corporate	0	0	0	0	0	0	0	0	0
Banks/Financial Institutions FI/FII	0	0	0	0	0	0	0	0	0
Any Others	0	0	0	0	0	0	0	0	0
<b>Sub-total (A) (1):-</b>	<b>0</b>	<b>3,00,000</b>	<b>3,00,000</b>	<b>100.00</b>	<b>0</b>	<b>2,60,100</b>	<b>2,60,100</b>	<b>86.70</b>	<b>0</b>
Foreign									
a) NRIs- Individuals	0	0	0	0	0	0	0	0	0
b) Other- Individuals	0	0	0	0	0	0	0	0	0
c) Bodies Corporate	0	0	0	0	0	0	0	0	0
d) Banks/FI	0	0	0	0	0	0	0	0	0
e) Any Others	0	0	0	0	0	0	0	0	0
<b>Sub-total (A) (2):-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total Shareholding of Promoter A=(A)(1)+(A)(2)</b>	<b>0</b>	<b>3,00,000</b>	<b>3,00,000</b>	<b>100.00</b>	<b>0</b>	<b>2,60,100</b>	<b>2,60,100</b>	<b>86.70</b>	<b>0</b>

CATEGORY OF SHAREHOLDERS	No. of shares held at the beginning of the year				No. of shares held at the end of the year				% change during the year
	Demat	Physical	Total	% of total shares	Demat	Physical	Total	% of total shares	
<b>B. PUBLIC SHAREHOLDING</b>									
<b>1. Institutions</b>									
a) Mutual Funds	0	0	0	0	0	0	0	0	0
b) Banks/FI	0	0	0	0	0	0	0	0	0
c) Central Govt.	0	0	0	0	0	0	0	0	0
d) State Govt.	0	0	0	0	0	0	0	0	0
e) Venture Capital Funds	0	0	0	0	0	0	0	0	0
f) Insurance companies	0	0	0	0	0	0	0	0	0
g) FIs	0	0	0	0	0	0	0	0	0
h) Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
i) Others (Trust)	0	0	0	0	0	0	0	0	0
<b>Sub-total (B) (1):-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>2. Non-Institutions</b>									
a) Bodies Corporate									
(i) Indian	0	0	0	0	0	0	0	0	0
(ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals									
(i) Individual shareholders holding nominal share capital upto Rs.1 Lakh	0	0	0	0	0	0	0	0	0
(ii) Individual shareholders holding nominal share capital in excess of Rs.1 Lakh	0	0	0	0	0	39,900	39,900	13.30%	0
(iii) Others (specify)	0	0	0	0	0	0	0	0	0
<b>Sub-total (B) (2):-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

Total Public Shareholding (B)= (B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by custodians for GDRs & ADRs	0	0	0	0	0	0	0	0	0
<b>Grand Total (A+B+C)</b>	<b>0</b>	<b>3,00,000</b>	<b>3,00,000</b>	<b>100.00</b>	<b>0</b>	<b>3,00,000</b>	<b>3,00,000</b>	<b>100.00</b>	<b>0</b>

**Note:** All Equity Shares issued by the Company are in PHYSICAL format and none in DEMAT format

## ii. SHAREHOLDING OF PROMOTERS

SI. NO	SHAREHOLDER'S NAME	SHAREHOLDING AT THE BEGINNING OF THE YEAR			SHAREHOLDING AT THE END OF THE YEAR			% CHANGE IN THE SHAREHOLDING DURING THE YEAR
		NO. OF SHARES	% OF TOTAL SHARES OF THE COMPANY	% OF SHARES PLEDGED / ENCUMBERED TO TOTAL SHARES	NO. OF SHARES	% OF TOTAL SHARES OF THE COMPANY	% OF SHARES PLEDGED / ENCUMBERED TO TOTAL SHARES	
1.	SRINIVASAN	1,00,000	33.33%	0	86,670	28.89%	0	(4.44)
2.	AJAY BABU NARAYANAM	50,000	16.67%	0	43,350	14.45%	0	(2.22)
3.	SWAPNA P	50,000	16.67%	0	43,360	14.45%	0	(2.22)
4.	JONNALAGADA SREEDEVI	50,000	16.67%	0	43,360	14.45%	0	(2.22)
5.	SRINIVAS GANGASHETTYWAR	50,000	16.67%	0	43,360	14.45%	0	(2.22)
<b>TOTAL</b>		<b>3,00,000</b>	<b>100.00%</b>	<b>-</b>	<b>2,60,100</b>	<b>86.70%</b>	<b>-</b>	<b>(13.33)</b>

## iii. CHANGE IN PROMOTERS' SHAREHOLDING (PLEASE SPECIFY IF THERE IS NO CHANGE)

S.No		Shareholding at the beginning of the year		Cumulative shareholding during the year	
		No. of Shares	% of total shares of the	No. of shares	% of total shares of the

			Company		
<b>1</b>	<b>SRINIVASAN</b>				
	At the beginning of the year	1,00,000	33.33%	1,00,000	33.33%
	Decrease in promoter's shareholding during the year due to transfer of shares dated 23 <sup>rd</sup> July 2024	-	-	-13,330	-4.44
	At the end of the year	1,00,000	33.33%	86,670	28.89%
<b>2</b>	<b>AJAY BABU NARAYANAM</b>				
	At the beginning of the year	50,000	16.67%	50,000	16.67%
	Decrease in promoter's shareholding during the year due to transfer of shares dated 23 <sup>rd</sup> July 2024	-	-	-6,650	-2.22
	At the end of the year	50,000	16.67%	43,350	14.45%
<b>3</b>	<b>SWAPNA P</b>				
	At the beginning of the year	50,000	16.67%	50,000	16.67%
	Decrease in promoter's shareholding during the year due to transfer of shares dated 23 <sup>rd</sup> July 2024	-	-	-6,640	-2.22
	At the end of the year	50,000	16.67%	43,360	14.45%
<b>4</b>	<b>JONNALAGADA SREEDEVI</b>				
	At the beginning of the year	50,000	16.67%	50,000	16.67%
	Decrease in promoter's shareholding during the year due to transfer of shares dated 23 <sup>rd</sup> July 2024	-	-	-6,640	-2.22
	At the end of the year	50,000	16.67%	43,360	14.45%
<b>5</b>	<b>SRINIVAS GANGASHETTYWAR</b>				
	At the beginning of the year	50,000	16.67%	50,000	16.67%
	Decrease in promoter's shareholding during the year due to transfer of shares dated 23 <sup>rd</sup> July 2024	-	-	-6,640	-2.22
	At the end of the year	50,000	16.67%	43,360	14.45%

\*The percentage of holding as on year end is adjusted with reference to the total number of Equity Shares as on 31<sup>st</sup> March, 2024

(iv) SHAREHOLDING PATTERN OF TOP TEN SHAREHOLDERS (OTHER THAN DIRECTORS, PROMOTERS AND HOLDERS OF ADRS & GDRS):

Sl. NO.	FOR EACH OF THE TOP TEN SHAREHOLDERS	SHAREHOLDING AT THE BEGINNING OF THE YEAR		CUMULATIVE SHAREHOLDING DURING THE YEAR	
		NO. OF SHARES	% OF TOTAL SHARES OF THE COMPANY	NO. OF SHARES	% OF TOTAL SHARES OF THE COMPANY
1	ARWA UMESH				
	At the beginning of the year	0	0.00%	39900	13.30%
	At the end of the year (or on the date of separation if separated during the year)	0	0.00%	39900	13.30%

(v) \*SHAREHOLDING OF DIRECTORS OR KEY MANAGERIAL PERSONNEL:

SL.NO	FOR EACH OF THE TOP TEN SHAREHOLDERS	SHAREHOLDING AT THE BEGINNING OF THE YEAR		CUMULATIVE SHAREHOLDING DURING THE YEAR	
		NO. OF SHARES	% OF TOTAL SHARES OF THE COMPANY	NO. OF SHARES	% OF TOTAL SHARES OF THE COMPANY
<b>DIRECTORS</b>					
	At the Beginning of the Year				
	Srinivasan	100000	33.33%	100000	33.33%
	Ajay Babu Narayanam	50000	16.67%	50000	16.67%
	Swapna P	50000	16.67%	50000	16.67%

Jonnalagada Sreedevi	50000	16.67%	50000	16.67%
Srinivas Gangashettywar	50000	16.67%	50000	16.67%
<b>Decrease in promoter's shareholding during the year due to transfer of shares dated 23rd July 2024</b>				
Srinivasan	-	-	13330	4.44%
Ajay Babu Narayanam	-	-	6650	2.22%
Swapna P	-	-	6640	2.22%
Jonnalagada Sreedevi	-	-	6640	2.22%
Srinivas Gangashettywar	-	-	6640	2.22%
<b>At the end of the year (or on the date of separation if separated during the year)</b>				
Srinivasan	100000	33.33%	86670	28.89%
Ajay Babu Narayanam	50000	16.67%	43350	16.67%
Swapna P	50000	16.67%	43360	16.67%
Jonnalagada Sreedevi	50000	16.67%	43360	16.67%
Srinivas Gangashettywar	50000	16.67%	43360	16.67%
<b>KEY MANAGERIAL PERSONNEL</b>				
<b>SRINIVASAN</b>				
<b>At the Beginning of the Year</b>			<b>1,00,000</b>	
Decrease in shareholding during the year due to transfer of shares dated 23 <sup>rd</sup> July 2024			<b>(13,330)</b>	
<b>At the end of the year (or on the date of separation if separated during the year)</b>			<b>86,670</b>	

**IV. INDEBTEDNESS OF THE COMPANY INCLUDING INTEREST OUTSTANDING/ACCRUED BUT NOT DUE FOR PAYMENT:**
*(Amount in Lakhs)*

	SECURED LOANS EXCLUDING DEPOSITS	UNSECURED LOANS	DEPOSITS (OVERDRAFT)	TOTAL INDEBTEDNESS
<b>Indebtedness at the beginning of the financial year</b>				
Principal Amount	1,124.58	712.17	-	1,836.75
Interest due but not paid	-	-	-	-
Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>1,124.58</b>	<b>712.17</b>	<b>-</b>	<b>1,836.75</b>
<b>Change in Indebtedness during the financial year:</b>				
Addition	125.30	0	-	11260.69
Reduction	0	-87.5	-	0
<b>Net Change</b>	<b>125.30</b>	<b>-87.5</b>	<b>-</b>	<b>11260.69</b>
<b>Indebtedness at the end of the financial year</b>				
Principal Amount	1249.88	624.67	-	1874.55
Interest due but not paid	0	0	-	-
Interest accrued but not due	0	0	-	-
<b>Total (i+ii+iii)</b>	<b>1249.88</b>	<b>624.67</b>	<b>-</b>	<b>1874.55</b>

**VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:**
**A. REMUNERATION TO MANAGING DIRECTOR, WHOLE-TIME DIRECTORS AND /OR MANAGER:**
*(Amount in Lakhs)*

Sl. NO.	PARTICULARS OF REMUNERATION	SRINIVASAN	TOTAL AMOUNT (In Rs.)
<b>1.</b>	Gross salary	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	66.00	66.00
	(b) Value of perquisites u/s 17(2) Income-tax Act,	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-
<b>2.</b>	Stock Option	-	-
<b>3.</b>	Sweat Equity	-	-

4.	Commission-as % of profit-others, specify...	-	
5.	Others,	-	-
	<b>Total (A)</b>	66.00	66.00
	Ceiling as per the Act		

**B. REMUNERATION TO OTHER DIRECTORS:**
*(Amount in Lakhs)*

Sl. NO	PARTICULARS OF REMUNERATION	Ajay Babu Narayana m	Srinivas Gangashettywa r	Venkata Nagendraprasa d Jonnalagadda	Jonnalgadd a Sridevi	Swapn a P	Rakesh Pasupunur i	TOTAL AMOUN T
	1. Independent Directors							
	<ul style="list-style-type: none"> <li>Fee for attending board committee meetings</li> </ul>							<i>Not Applicable</i>
	<ul style="list-style-type: none"> <li>Commission</li> </ul>							

	• Others, please specify					
	<b>Total (1)</b>					
	2. Other Non-Executive Directors					
	• Fee for attending board committee meetings	0	0	0	0	0
	• Commission	0	0	0	0	0

	• Others (Salary)	53.7	53.7	24.00	29.70	29.70	24.00	214.80
	<b>Total (2)</b>	<b>53.7</b>	<b>53.7</b>	<b>24.00</b>	<b>29.70</b>	<b>29.70</b>	<b>24.00</b>	<b>214.80</b>
	<b>Total (B)=(1+2)</b>	<b>53.7</b>	<b>53.7</b>	<b>24.00</b>	<b>29.70</b>	<b>29.70</b>	<b>24.00</b>	<b>214.80</b>
	<b>Total Managerial Remuneration</b>	<b>53.7</b>	<b>53.7</b>	<b>24.00</b>	<b>29.70</b>	<b>29.70</b>	<b>24.00</b>	<b>214.80</b>
	Overall Ceiling as per the Act							

**C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD / MANAGER / WTD**

Sl. NO.	PARTICULARS OF REMUNERATION	KEY MANAGERIAL PERSONNEL			
		CEO	COMPANY SECRETARY	COO	TOTAL
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	NA	NA	NA	NA
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	NA	NA	NA	NA
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	NA	NA	NA	NA
2.	Stock Option	NA	NA	NA	NA
3.	Sweat Equity	NA	NA	NA	NA
4.	Commission-as % of profit-others, specify...	NA	NA	NA	NA
5.	Others, please specify	NA	NA	NA	NA
	Total	NA	NA	NA	NA

**VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:**



**SAI PRIMUS LIFE**  
Appeal made, if any (give details)

Type	Section of the Companies Act	Brief description	Details of penalty/ punishment/ compounding fees imposed	Authority (RD/NCLT/Court)	Appeal made, if any (give details)
<b>A. Company</b>					
Penalty	NA	NA	NA	Nil	Nil
Punishment	NA	NA	NA	Nil	Nil
Compounding	NA	NA	NA	Nil	Nil
<b>B. Directors</b>					
Penalty	NA	Nil	Nil	Nil	Nil
Punishment	NA	Nil	Nil	Nil	Nil
Compounding	NA	Nil	Nil	Nil	Nil
<b>C. Other Officers in default</b>					
Penalty	NA	Nil	Nil	Nil	Nil
Punishment	NA	Nil	Nil	Nil	Nil
Compounding	NA	Nil	Nil	Nil	Nil

For SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED

AJAY BABU NARAYANAM  
DIRECTOR  
DIN: 02929155

E. SRINIVASAN  
MANAGING DIRECTOR  
DIN: 03106171

PLACE: PONDICHERRY  
DATE: 05/09/2025



**ANNEXURE – II**

**FORM AOC-2**

*(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)*

**Name of the Company : SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED**  
**CIN : U24304PY2017PTC008147**

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms' length transactions under third proviso thereto

**(a) Details of material contracts or arrangements or transactions not at arm's length basis:**

S.No.	Particulars	Details
1	Name(s) of the related party and nature of relationship	Not applicable
2	Nature of contracts/arrangements/transactions	
3	Duration of the contracts / arrangements/ transactions	
4	Salient terms of the contracts or arrangements or transactions including the value, if any	
5	Justification for entering into such contracts or arrangements or transactions	
6	Date(s) of approval by the Board	
7	Amount paid as advances, if any	
8	Date on which the special resolution was passed in general meeting as required under first proviso to section 188	

**(b) Details of material contracts or arrangements or transactions at arm's length basis:**

*(Amount if any in Lakhs)*


S.No.	Name(s) of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts / arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Date(s) of approval by the Board	Amount paid as advances, if any
1	PRIMUS REMEDIES PRIVATE LIMITED	SALE OF GOODS	Continuous	Ordinary Course of	-	-

	(Entity in which Director is interested)			Business – Value of Transaction - Rs. 1432.65		
2	LIFECARE FORMULATIONS PRIVATE LIMITED (Entity in which Director is interested)	UNSECURED LOAN GIVEN	Continuous	Ordinary Course of Business - Value of Transaction - Rs. 66.55	-	-
3	LIFECARE FORMULATIONS PRIVATE LIMITED (Entity in which Director is interested)	REPAYMENT OF LOAN GIVEN	Continuous	Ordinary Course of Business - Value of Transaction - Rs. 58.78	-	-
4	E.SRINIVASAN	REMUNERATION	Continuous	Ordinary Course of Business – Value of Transaction - Rs.6,600	-	-
5	E.SRINIVASAN	REPAYMENT OF LOAN GIVEN	Continuous	Ordinary Course of Business – Value of Transaction - Rs.1,750	-	-
5	AJAY BABU NARAYANAM	REMUNERATION	Continuous	Ordinary Course of Business – Value of Transaction - Rs.5,370	-	-

6	AJAY BABU NARAYANAM	REPAYMENT OF LOAN GIVEN	Continuous	Ordinary Course of Business – Value of Transaction - Rs.1,750	-	-
7	SRINIVAS GANGASHETTYWA R	REMUNERATION	Continuous	Ordinary Course of Business – Value of Transaction - Rs.5,370	-	-
8	SRINIVAS GANGASHETTYWA R	REPAYMENT OF LOAN GIVEN	Continuous	Ordinary Course of Business – Value of Transaction - Rs.1,750	-	-
9	JONNALAGADDA VENKATA NAGENDRAPRASA D	REMUNERATION	Continuous	Ordinary Course of Business – Value of Transaction - Rs.2,400	-	-
10	JONNALAGADDA SREEDEVI	REMUNERATION	Continuous	Ordinary Course of Business – Value of Transaction - Rs.2,970	-	-
11	JONNALAGADDA SREEDEVI	REPAYMENT OF LOAN GIVEN	Continuous	Ordinary Course of Business – Value of Transaction - Rs.1,750	-	-
12	SWAPNA P	REMUNERATION	Continuous	Ordinary	-	-

				Course of Business – Value of Transaction - Rs.2,970		
13	SWAPNA P	REPAYMENT OF LOAN GIVEN	Continuous	Ordinary Course of Business – Value of Transaction - Rs.1,750	-	-
14	RAKESH PASUPUNURI	REMUNERATION	Continuous	Ordinary Course of Business – Value of Transaction - Rs.2,400	-	-

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF  
SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED



**AJAY BABU NARAYANAM**  
DIRECTOR  
DIN: 02929155



**E. SRINIVASAN**  
MANAGING DIRECTOR  
DIN: 03106171

PLACE: PONDICHERRY  
DATE: 05/09/2025





**Independent Auditor's Report**

To the Members of Sai Primus Lifebiotech Private Limited  
Report on the Audit of Financial Statements

**Opinion**

1. We have audited the accompanying financial statements of **Sai Primus Lifebiotech Private Limited**, which comprise the Balance Sheet as at 31<sup>st</sup> March 2025, the Statement of Profit and Loss, the Statement of Cash Flows for the year then ended, and a summary of the significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31<sup>st</sup> March 2025, its profit, its cash flows for the year ended on that date.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.
4. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Information other than the Financial Statements and Auditor's Report thereon**

5. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the financial statements and our auditor's report thereon.



6. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of Management for the Financial Statements**

7. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, profit or loss, cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards ('AS') specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
8. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
9. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

10. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



11. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- a. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
  - b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
  - c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
  - d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
  - e. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
12. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
13. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Report on Other Legal and Regulatory Requirements**

14. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the Order.



15. Further to our comments in Annexure A, as required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) The financial statements dealt with by this report are in agreement with the books of account;
- d) In our opinion, the aforesaid financial statements comply with Accounting Standards(AS) specified under Section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;
- e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March 2025 from being appointed as a director in terms of Section 164(2) of the Act;
- f) We have also audited the internal financial controls over financial reporting (IFCOFR) of the Company as on 31st March 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date and our report dated 5th September 2025 as per Annexure B expressed an unmodified opinion;
- g) The Provision of Sec.197 of the Act is not applicable to the Company, as the company is private limited company.
- h) with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company has disclosed the impact of pending litigations as at 31<sup>st</sup> March 2025 on its financial position in its financial statements –Refer Note. 12 (i&ii) to the financial statements;
  - ii. the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv.
    - a) The management has represented that to the best of its knowledge and belief, no funds(which are material either individually or in the aggregate) have been advanced or loaned or invested(either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entity(intermediaries), with the understanding directly or indirectly lend or invest in other persons or entity's identified in any manner



whatsoever by or on behalf of the company(ultimate beneficiaries) or provide any guarantee, security or the like on behalf of the ultimate beneficiaries;

- b) The management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity (Funding Parties), with the understanding whether recorded in writing or otherwise , that the company shall directly or indirectly lend or invest in other persons or entity's identified in any manner whatsoever by or on behalf of the Funding Party (ultimate beneficiaries) or provide any guarantee, security or the like on behalf of the ultimate beneficiaries.
- c) Based on the audit procedures that have been considered that are reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub clause (i) and (ii) of rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. During the financial year, the company has not declared any dividend, hence reporting under these clauses is not applicable.
- vi. Based on our examination, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2025 which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2025.

Place: Hyderabad  
Date: 05.09.2025

For M/s. Pinnaka & Co.  
Firm Registration No: 008813S  
Chartered Accountants



CA. Ramesh Babu Pinnaka  
Proprietor

Membership No. 209481

UDIN: 25209481BMFXXJ3821





**Annexure A to the Independent Auditors' Report of even date to the members of Sai Primus Lifebiotech Private Limited, on the financial statements for the year ended 31<sup>st</sup> March 2025**

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

**i. In Respect of its Property, Plant & Equipment:**

(a)

- A. The company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant & Equipment;
- B. The Company does not have any intangible assets.

(b) The Company has a program of physical verification of Property, Plant and Equipment so to cover all the assets once in every year which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were due for verification during the year and were physically verified by the Management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) Based on our examination of the property tax receipts and lease agreement for land on which buildings is constructed, registered sale deed / transfer deed/ conveyance deed provided to us, we report that, the title in respect of self- constructed buildings and title deeds of all other immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favor of the lease), disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.

(d) The company has not revalued any of its property, plant and Equipment during the year and company does not have any intangible assets.

(e) No proceedings have been initiated during the year or pending against the company as at March 31, 2025 for holding any Benami property under Benami transaction (Prohibition) Act, 1988 (As amended in 2016) and rules made thereunder.

**ii.**

(a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable, and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.



- (b) The company has working capital limits of Rs. 5 crores during the year from Indian bank on the basis of security of current assets and the quarterly returns or statements filed by the company with Axis bank are in agreement with the books of account of the company.
- iii. According
- (a) During the year, the company has not provided any guarantees:
- (b) During the year, the Company has not granted loans, advance in nature of loans, stood guarantee or provided any security to firms and Limited Liability partnerships.
- (c) The schedule of repayment in respect of loans granted for principal and interest payments has been stipulated and the repayment or receipts are regular, and accrued interest has been capitalised at year end with the amount of outstanding loans, as per the terms of the agreement.
- (d) There are no amounts of loans and advances in the nature of loans granted to companies which are overdue for more than ninety days.
- (e) There were no loans or advances in the nature of loans granted to companies which has fallen due during the year based on the tenure of respective loan agreements.
- (f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the Company.
- iv. On the basis of information and explanations provided to us by the management, in compliance with the provisions of Section 185 and 186 of the Companies Act, 2013 the Company has not provided guarantee entities in which directors are interested and also the company has not made any investments in entities in which directors are interested.
- v. The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptances of Deposits) Rules, 2014(as amended). Accordingly, the provisions of clauses 3(v) of the Order not applicable.
- vi. We have broadly reviewed books of account maintained by the company pursuant to the rules made by the central government for maintenance of cost records under section 148(1) of the Companies Act, 2013, and are of the opinion that *prima facies*, the prescribed accounts and records have been made and maintained.
- vii.
- (a) The company is generally regular in depositing undisputed statutory dues including Goods and service tax, Provident fund, employees' state insurance, income-tax, service tax, Duty of customs, duty of excise, value added tax, cess and any other material statutory Dues, as applicable to the appropriate authorities.



According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, goods and service tax, duty of customs and any other material statutory dues in arrears as at March 31, 2025 for a period of more than six months from the date they became payable.

- (b) There were no dues in respect of income-tax, duty of customs, Cess and any other material statutory dues that have not been deposited with the appropriate authorities on account of any dispute.
- viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- ix.
- (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- (c) According to the information and explanations given to us by the management, the Company has obtained term loans during the year and the proceeds of the term loan were applied for the purpose for which the loans were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.
- (e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures as defined under the Act.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies (as defined under Companies Act, 2013).
- x.
- (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x) (b) of the Order is not applicable.



- xi.
- (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
- xii. According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- xiii. In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act 2013.
- xv. In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi.
- (a) In our opinion and according to the information and explanations given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) & (b) of the Order is not applicable.
- (b) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (c) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi) (d) are not applicable.
- xvii. The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors during the year and accordingly this clause is not applicable.



- xix. On the basis of the financial ratios disclosed to the financial statements, the ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Management / Board of Directors business plan and based on our examination of evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that Company is not capable of meeting its liabilities, existing at the date of balance sheet, as and when they fall due within a period of one year from the balance sheet date.


We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from balance sheet date, will get discharged by the Company as and when they fall due.

xx.

- (a) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project other than ongoing projects. Accordingly, clause 3(xx)(a) of the Order is not applicable.
- (b) The Company has no obligation to undertake any CSR projects, Accordingly, clause 3(xx)(b) of the Order is not applicable.

Place: Hyderabad  
Date: 05.09.2025

For M/s. Pinnaka & Co.  
Firm Registration No: 008813S  
Chartered Accountants



CA. Ramesh Babu Pinnaka

Proprietor

M.No.209481

UDIN: 25209481BMFXXJ3821





**Annexure B to The Independent Auditor's Report of Even Date to the members of Sai Primus Lifebiotech Private Limited, on the financial statements for the year ended 31<sup>st</sup> March 2025**

**Independent Auditor's Report on the Internal Financial Controls under Clause(i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **Sai Primus Lifebiotech Private Limited** ("the Company") as of March 31, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial Controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.



**Chamber:**

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that: 1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; 2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and 3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: Hyderabad

Date: Sep 5, 2025

For M/s. Pinnaka & Co.  
Firm Registration No: 008813S  
Chartered Accountants



CA. Ramesh Babu Pinnaka  
Proprietor

M.No.209481

UDIN: 25209481BMFXXJ3821



# SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED

R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, India, 605009

CIN : U24304PY2017PTC008147

**BALANCE SHEET AS AT MARCH 31, 2025**

*(All amounts are in INR in Lakhs unless otherwise stated)*

PARTICULARS	NOTE	AS AT	
		MAR 31, 2025	MAR 31, 2024
<b>I. EQUITY AND LIABILITIES</b>			
<b>1 Shareholders' Funds</b>			
(a) Share Capital	3	30.00	30.00
(b) Reserves and Surplus	4	1,025.95	334.85
		<b>1,055.95</b>	<b>364.85</b>
<b>2 Non-Current Liabilities</b>			
(a) Long-Term Borrowings	5	1,064.81	1,394.64
(b) Long-Term Provisions	6	57.16	-
		<b>1,121.97</b>	<b>1,394.64</b>
<b>3 Current Liabilities</b>			
(a) Short-Term Borrowings	7	809.75	442.11
(b) Trade Payables	8		
(A) Total Outstanding Dues of Micro and Small Enterprises		-	-
(B) Total Outstanding Dues of Creditors Other than Micro and Small Enterprises		2,374.81	1,306.42
(c) Other Current Liabilities	9	1,142.97	117.23
(d) Short-Term Provisions	10	154.18	84.47
		<b>4,481.70</b>	<b>1,950.24</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>6,659.62</b>	<b>3,709.73</b>
<b>II. ASSETS</b>			
<b>1 Non-Current Assets</b>			
(a) Property, Plant & Equipment and Intangible Assets			
(i) Property, Plant & Equipment	11(a)	1,472.72	1,488.21
(ii) Intangible Assets	11(b)	20.97	-
(iii) Capital work In progress	11(c)	106.80	-
(iv) Intangible Assets under Development	11(d)	58.03	-
(b) Deferred Tax Asset (Net)	12	(111.76)	11.81
(c) Long Term Loans and Advances	13	21.00	18.29
(d) Other Non-Current Assets	14	26.05	25.82
		<b>1,593.81</b>	<b>1,544.13</b>
<b>2 Current Assets</b>			
(a) Inventories	15	3,137.32	1,362.60
(b) Trade Receivables	16	1,080.62	555.61
(c) Cash & Cash Equivalents	17	20.73	15.29
(d) Short term loans and advances	18	443.71	94.32
(e) Other Current Assets	19	383.43	137.79
		<b>5,065.81</b>	<b>2,165.60</b>
<b>TOTAL ASSETS</b>		<b>6,659.62</b>	<b>3,709.73</b>

Significant accounting policies

2


See accompanying notes to the financial statements

As per our report of even date

**For Pinnaka & Co**

Firm Reg. No. 0088135

Chartered Accountants




**CA Ramesh Babu Pinnaka**


Proprietor

Membership No. 209481

UDIN: 25209481BMFXXJ3821

Date: 05-09-2025

For and on behalf of the Board of  
**SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED**



**AJAYBABU NARAYANAM**  
Director  
DIN: 02929155



**E SRINIVASAN**  
Managing Director  
DIN: 03106171

# SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED

R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, India, 605009

CIN : U24304PY2017PTIC008147


## STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED MARCH 31, 2025

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	NOTE	FOR THE YEAR ENDED	
		MAR 31, 2025	MAR 31, 2024
<b>I. Income</b>			
Revenue From Operations	20	7,897.80	5,638.06
Other Income	21	44.37	15.07
<b>Total Revenue</b>		<b>7,942.17</b>	<b>5,653.12</b>
<b>II Expenditure</b>			
(a) Direct Operating Expense	22	4,617.73	3,253.00
(b) Employee Benefit Expenses	23	1,363.50	1,008.98
(c) Finance Costs	24	147.67	124.24
(d) Depreciation & Amortisation Expenses	25	118.80	118.55
(e) Other Expenses	26	727.63	654.31
<b>Total Expenditure</b>		<b>6,975.33</b>	<b>5,159.08</b>
<b>III Profit Before Exceptional and Extraordinary Items and Tax (I-II)</b>		<b>966.84</b>	<b>494.04</b>
<b>IV Exceptional and Extraordinary Items</b>		-	-
<b>V Profit/(Loss) Before Tax (III-IV)</b>		<b>966.84</b>	<b>494.04</b>
<b>VI Tax Expense:</b>			
(a) Current Tax		152.17	86.46
(b) Deferred Tax		123.57	86.17
<b>VII Profit/(Loss) for the Year After Tax (V-VI)</b>		<b>691.09</b>	<b>321.42</b>
<b>VIII Earnings per Equity Share of Rs.10 Each</b>			
- Basic		230.36	107.14
- Diluted		230.36	107.14
Weighted Average No. of Shares (In Absolute Values)		3,00,000	3,00,000
Significant accounting policies	2		
See accompanying notes to the financial statements			

As per our report of even date

For Pinnaka & Co  
Firm Reg. No. 0088135  
Chartered Accountants



CA Ramesh Babu Pinnaka  
Proprietor  
Membership No. 209481  
UDIN: 25209481BMFXXJ3821  
Date: 05-09-2025



For and on behalf of the Board of  
SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED



AJAYBABU NARAYANAM  
Director  
DIN: 02929155



E SRINIVASAN  
Managing Director  
DIN: 03106171

# SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED

R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, India, 605009  
CIN : U24304PY2017PTC008147

## STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2025

(All amounts are in INR in Lakhs unless otherwise stated)

Particulars	For the Year Ended	
	Mar 31, 2025	Mar 31, 2024
<b>A CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net Profit Before Tax	966.84	494.04
<b>Adjustments for:</b>		
Depreciation	118.80	118.55
Interest Expenses	147.67	124.24
Unrealised Foreign Exchange Loss/(Gain)	(10.73)	
Provision for Gratuity	57.16	-
Prior Period Incomes/Expenses	-	(1.71)
<b>Operating Profit before working capital changes:</b>	<b>1,279.74</b>	<b>735.12</b>
<b>Adjustments for Changes in Working Capital:</b>		
(Increase)/Decrease in Trade Receivables	(525.01)	256.76
(Increase)/Decrease in Inventories	(1,774.73)	(252.99)
(Increase)/Decrease in Short term loans and Advances	(349.39)	(29.04)
(Increase)/Decrease in Other Current Assets	(245.64)	136.32
Increase/(Decrease) in Trade and Other Payables	1,068.39	(637.75)
Increase/(Decrease) in Short Term Borrowings	367.64	158.50
Increase/(Decrease) in Other Current Liabilities	1,025.73	53.44
<b>Cash Generated from Operations</b>	<b>846.74</b>	<b>420.36</b>
Income Taxes Paid	(82.47)	(25.69)
<b>NET CASH FROM OPERATING ACTIVITIES (A)</b>	<b>764.27</b>	<b>394.67</b>
<b>B CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Long term Advances	(2.72)	(14.53)
(Increase)/Decrease in Other Non-Current Assets	(0.24)	12.61
Purchase of Property, Plant and Equipment	(289.11)	(98.90)
<b>NET CASH USED IN INVESTING ACTIVITIES (B)</b>	<b>(292.06)</b>	<b>(100.81)</b>
<b>C CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Interest paid	(147.67)	(124.24)
Increase / (Decrease) in Long-Term Borrowings	(329.83)	(169.70)
<b>NET CASH USED IN FINANCING ACTIVITIES (C)</b>	<b>(477.51)</b>	<b>(293.94)</b>
Exchange difference on Realized (Loss)/Gain	10.73	-
<b>D NET INCREASE IN CASH AND CASH EQUIVALENT (A+B+C)</b>	<b>5.44</b>	<b>(0.09)</b>
Opening Cash and Cash Equivalents	15.29	15.37
<b>CLOSING CASH AND CASH EQUIVALENT</b>	<b>20.73</b>	<b>15.29</b>
<b>Reconciliation Of Cash And Cash Equivalents With The Balance Sheet:</b>		
Cash & Cash Equivalent as per Balance sheet	20.73	15.29
Cash & Cash Equivalent at the End of the Period	20.73	15.29
Significant accounting policies	2	
See accompanying notes to the financial statements		

As per our report of even date

**For Pinnaka & Co**  
Firm Reg. No. 0088135  
Chartered Accountants



**CA Ramesh Babu Pinnaka**  
Proprietor  
Membership No. 209481  
UDIN: 25209481BMFXXJ3821  
Date: 05-09-2025

For and on behalf of the Board of  
**SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED**

  
**AJAYBABU NARAYANAM**  
Director  
DIN: 02929155

  
**E SRINIVASAN**  
Managing Director  
DIN: 03106171

## SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED

R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, India, 605009

CIN : U24304PY2017PTC008147

### I. CORPORATE INFORMATION

SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED having CIN: U24304PY2017PTC008147 was incorporated on March 24th, 2017 under the provisions of the Companies Act 2013, and has its registered office at R.S.No.4/3, Plot No.33, Kurumbapet, Pondicherry, India, 605009.

The Main Object of the Company is:

- 1) To manufacture, formulate, process, develop, refine, import, export, wholesale and/or retail trade all kinds of pharmaceuticals, antibiotics, drugs, medicines, biologicals, nutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, wines, cordials, liquors, soups, broths and other restoratives or foods and also to deal in medicinal goods such as surgical instruments, contraceptives, photographic goods, oils, perfumes, cosmetics, patent medicines, soaps, artificial limbs, hospital requisites, proprietary medicines, veterinary medicines and tinctures extracts and to carry on the business of vialling, bottling, repacking, processing of tablets, capsules, syrups, injections, ointments, etc. and also to carry on the business of chemists, druggists, buyers, sellers, agents, distributors and stockists of all kinds of pharmaceuticals and allied products.
- 2) To establish and run health portal, web sites, medical transcription centres, data processing/computer centres, retail chains, e-commerce, and to offer wholesale, retail, e-commerce facilities, health consultancy and data processing and other services that are normally offered by health portal, web sites, medical transcription centres, data processing/computer centres, retail chains, etc. to individuals, business and other type of customers

### 2. SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO FINANCIAL STATEMENTS

#### 1 Basis of Preparation:

The financial statements of the Company have been prepared and presented in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other relevant provisions of the Act, as applicable.

These financial statements have been prepared under the historical cost convention on an accrual basis and in accordance with Schedule III (Division I) to the Companies Act, 2013 for presentation and disclosure requirements. The accounting policies adopted in the preparation of these financial statements are consistent with those followed in the previous year, unless otherwise stated. The financial statements have been prepared on the assumption that the Company is a going concern, and will continue its operations for the foreseeable future in the normal course of business.

#### 2 Use of Estimates:

The preparation of the financial statements in conformity with Generally Accepted Accounting Principles requires the Management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent assets and liabilities as at the date of the financial statements and the reported amounts of income and expenses during the year. Examples of such estimates include provisions for doubtful debts, income taxes and the useful lives of Property Plant and Equipments and intangible assets.



**3 Current and non-current classification:**

The Company presents assets and liabilities in the Balance Sheet based on current/ non-current classification.

An asset is classified as current when it satisfies any of the following criteria:

- It is expected to be realized or intended to be sold or consumed in normal operating cycle
- It is held primarily for the purpose of trading
- It is expected to be realized within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

A liability is current when it satisfies any of the following criteria:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

Current liabilities includes the current portion of long term financial liabilities. The Company classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities. The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

**4 Property, Plant and Equipment including Intangible Assets:**

Property, Plant and Equipments are stated at cost, less accumulated depreciation. Cost includes cost of acquisition including material cost, freight, installation cost, duties and taxes, and other incidental expenses, incurred up to the installation stage, related to such acquisition. Property, Plant and Equipments purchased in India in foreign currency are recorded in Rupees, converted at the exchange rate prevailed on the date of purchase. Intangible assets that are acquired by the Company are measured initially at cost. After initial recognition, an intangible asset is carried at its cost less any accumulated amortisation and any accumulated impairment loss. Subsequent expenditure is capitalized only when it increases the future economic benefits to the specific assets to which it relates. Intangible assets are amortized in Statement of Profit and Loss over their estimated useful lives, from the date that they are available for use based on the expected pattern of consumption of economic benefits of the assets.

**5 Depreciation & Amortisation:**

The Company has applied the estimated useful lives as specified in Schedule II of the Companies Act 2013 and calculated the depreciation as per the Straight Line Method. Depreciation on new assets acquired during the year is provided at the rates applicable from the date of acquisition to the end of the financial year. In respect of the assets sold during the year, depreciation is provided from the beginning of the year till the date of its disposal. Intangible assets are amortised on a straight-line basis over the estimated useful life as specified in Schedule II of the Companies Act 2013. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss. In respect of the assets sold during the year, amortisation is provided from the beginning of the year till the date of its disposal.

The estimated useful lives of assets are as follows:

Useful life of Property, Plant and Equipments

Category	Schedule - II Part 'C'	Useful life
Vehicles	VI (3)	8 Years
Office Equipment	XI	5 Years
Furniture & Fittings	V (i)	10 Years

**6 Capital work-in-progress:**

Capital Work-in-Progress represents costs incurred on assets under construction or development, which are not yet ready for intended use. It includes direct costs, attributable indirect costs, and eligible borrowing costs. CWIP is carried at cost and transferred to fixed assets upon completion. It is periodically reviewed for impairment, and any loss is recognized in the profit and loss statement.

**7 Investments:**

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long-term investments. Current investments are stated at lower of cost and fair value. Long-term investments are stated at cost. A provision for diminution is made to recognise a decline, other than temporary, in the value of long-term investments.



**8 Inventories:**

Inventories are carried at the lower of cost or net realisable value. Cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. In determining the cost, FIFO method is used. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-item basis.

**9 Cash and Cash Equivalents:**

Cash and Cash Equivalents comprise cash on hand and cash deposits with banks. The Company considers all highly liquid investments with a original maturity at a date of purchase of three months or less and that are readily convertible to known amounts of cash to be Cash Equivalents.

**10 Cash Flow Statement:**

Cash flows are reported using indirect method, whereby net profit/loss before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

**11 Revenue Recognition:**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured in accordance with AS-9, Revenue Recognition. Revenue from the sale of pharmaceutical and Nutraceutical products is recognized when significant risks and rewards of ownership are transferred to the customer, which generally coincides with dispatch/delivery of goods as per the terms of sale, and no significant uncertainty exists regarding the amount of consideration or ultimate collection. Export revenue is recognized upon shipment of goods in accordance with the agreed export terms.

The following other revenues are recognized and accounted on their accrual with necessary provisions for all known liabilities and losses as per AS 9:

**Interest Income:** Revenue is recognized on the time proportion basis after taking into account the amount outstanding and the rate applicable.

**Dividend Income:** Dividend Income is recognised when the owners right to receive payment is established.

**Other Income:** Other items of income and expenditure are recognized on accrual basis and as a going concern basis, and the accounting policies are consistent with the generally accepted accounting policies.

**12 Foreign Currency Transactions:**

**Domestic Operation:**

**I. Initial Recognition :**

A foreign currency transaction is accounted in accordance with AS-11 "The Effects of Changes in Foreign Exchange Rates", on initial recognition in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

**II. Measurement :**

Foreign currency monetary items are reported using the closing rate.

Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction.

Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

**III. Treatment of Foreign Exchange :**

Exchange differences arising on settlement of foreign currency monetary assets and liabilities of the Company are recognised as income or expenses in the Statement of Profit and Loss.



**13 Employee Benefits:**

**Post-Employment Benefits:**

**Defined Benefit Plan:**

Gratuity liability is a defined benefit obligation and is unfunded. The Company accounts for liability for future gratuity benefits based on the actuarial valuation using Projected Unit Credit Method carried out as at the end of each financial

**Defined Contribution Plan:**

Provident Fund: Eligible employees receive benefit from provident fund covered under the Provident Fund Act. Both the employee and the company make monthly contributions. The employer contribution is charged off to Profit & Loss Account as an expense.

**Short-term Employee Benefits:**

Short-Term Employee Benefits are recognized as an expense in the period in which the related service is rendered. These include salaries, wages, bonuses, leave encashment, and other benefits payable within twelve months.

**14 Leases:**

Leased assets under which the Company assumes substantially all risks and rewards of ownership are classified as finance leases. Other leases are classified as operating leases.

**Finance Leases:**

Assets taken on finance lease are capitalized at the lower of the fair value of the asset and the present value of minimum lease payments, with a corresponding lease liability recognized. The principal component of lease payments is adjusted against the lease liability and the interest component is charged to the Statement of Profit and Loss.

The Company has not entered into any finance lease arrangements during the reporting period.

**Operating Leases:**

Lease rentals in respect of assets taken on operating lease are charged to the Statement of Profit and Loss over the lease term on a straight-line basis unless another systematic basis is more representative of the time pattern of the user's benefit.

The Company has not entered into any operating lease arrangements during the reporting period.

**15 Borrowing Costs:**

Borrowing costs attributable to the acquisition or construction of a qualifying asset are capitalised as part of the cost of the asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. Other borrowing costs are recognised as an expense in the period in which they are incurred.

**16 Taxes on Income:**

Income Tax expense is accounted in accordance with AS-22 'Accounting for Taxes on Income' for both Current Tax and Deferred Tax stated below:

**A. Current Tax:**

Provision for current tax is made in accordance with the provisions of the Income Tax Act, 1961.

**B. Deferred Tax:**

The differences that result between the profit/(loss) considered for income taxes and the profit / (loss) as per the financial statements are identified and thereafter a deferred tax asset or deferred tax liability is recorded for timing differences, namely the differences that originate in one accounting period and reverse in another, based on the tax effect of the aggregate amount being considered. The tax effect is calculated on the accumulated timing differences at the end of an accounting period based on tax rates that have been enacted or substantially enacted by the Balance Sheet date.

Where there are unabsorbed depreciation or carry forward losses, deferred tax assets are recognised only to the extent there is virtual certainty of realisation of such assets. In other situations, deferred tax assets are recognised only to the extent there is reasonable certainty of realisation in future. Such assets are reviewed at each Balance Sheet date and written down or written up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

**17 Provisions and Contingent Liabilities:**

A provision is recognised if, as a result of past event, the Company has a present legal obligation that can be estimated reliably and it is probable that an outflow of economic benefit will be required to settle the obligation. Provisions are determined by the best estimate of outflow of economic benefits required to settle the obligation at the reporting date. Where no reliable estimate can be made, a disclosure is made as contingent liability. A disclosure for a contingent liability is also made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is possible obligation or present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

**18 Earnings Per Share:**

Basic Earnings per share is computed by dividing the net profit after tax by the weighted average number of equity shares outstanding during the period. Diluted earnings per share is computed by dividing the net profit after tax by the weighted average number of shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. The diluted potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value which is the average market value of the outstanding shares. Dilutive potential equity shares are deemed converted as at the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented.



## SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED

R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, India, 605009  
CIN : U24304PY2017PTC008147

### Notes to the Financial Statements

Note No. 3

#### SHARE CAPITAL

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	As at March 31, 2025	As at March 31, 2024
<b>Authorised Share Capital</b>		
<b>Equity shares of Rs.10/ each (in numbers)</b>		
No. of shares at the beginning of the period	20,00,000	20,00,000
No. of shares Increase / (Decrease) during the period	-	-
No. of shares outstanding at the end of the period	20,00,000	20,00,000
<b>Equity shares of Rs.10/ each (in value)</b>		
Shares at the beginning of the period	200.00	200.00
Increase / (Decrease) during the period	-	-
Shares outstanding at the end of the period	200.00	200.00
<b>Issued, Subscribed &amp; Fully Paid Up</b>		
<b>Equity shares of Rs.10/ each (in numbers)</b>		
No. of shares at the beginning of the period	3,00,000	3,00,000
No. of shares Increase / (Decrease) during the period	-	-
No. of shares outstanding at the end of the period	3,00,000	3,00,000
<b>Equity shares of Rs.10/ each (in value)</b>		
Shares at the beginning of the period	30.00	30.00
Increase / (Decrease) during the period	-	-
Shares outstanding at the end of the period	30.00	30.00
<b>Total</b>	<b>30.00</b>	<b>30.00</b>

#### RECONCILIATION OF NUMBER OF SHARES OUTSTANDING

PARTICULARS	As at March 31, 2025	As at March 31, 2024
At the beginning of the year	3,00,000	3,00,000
Shares Issued for consideration during the year	-	-
Shares bought back during the year	-	-
<b>Total Outstanding at the end of the year</b>	<b>3,00,000</b>	<b>3,00,000</b>

#### Rights, preferences and restrictions attached to equity shares:

The Company has only one class of equity shares having a par value of ₹ 10/- per share. Each holder of equity shares is entitled to one vote per share. The dividend, if any, proposed by the Board of Directors is subject to the approval of the shareholders at the ensuing annual general meeting. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts in the proportion of equity shares held.

#### DETAILS OF SHAREHOLDING OF PROMOTER & PROMOTER GROUP:

NAME OF PROMOTER AND PROMOTER GROUP	As at March 31, 2025		As at March 31, 2024	
	No. of shares Held	% Holding	No. of shares Held	% Holding
<b>Equity shares of Rs. 10 each fully paid-up</b>				
E Srinivasan	86,670	28.89%	1,00,000	33.33%
% Change during the year/ Period *	(14.44%)		0.00%	
Ajay Babu Narayanam	43,350	14.45%	50,000	16.67%
% Change during the year/ Period *	(12.99%)		0.00%	
Srinivas Gangashettywar	43,360	14.45%	50,000	16.67%
% Change during the year/ Period *	(12.97%)		0.00%	
Sridevi Jomalagadda	43,360	14.45%	50,000	16.67%
% Change during the year/ Period *	(12.92%)		0.00%	
Swapna Pasupunuri	43,360	14.45%	50,000	16.67%
% Change during the year/ Period *	(12.92%)		0.00%	

\* The % change mentioned here denotes the absolute change of share percentage during the period.

#### DETAILS OF SHAREHOLDERS HOLDING MORE THAN 5% OF SHARES:

NAME OF SHAREHOLDERS	As at March 31, 2025		As at March 31, 2024	
	No. of shares Held	% Holding	No. of shares Held	% Holding
<b>Equity shares of Rs. 10 each fully paid-up</b>				
E Srinivasan	86,670	28.89%	1,00,000	33.33%
Ajay Babu Narayanam	43,350	14.45%	50,000	16.67%
Srinivas Gangashettywar	43,360	14.45%	50,000	16.67%
Sridevi Jomalagadda	43,360	14.45%	50,000	16.67%
Swapna Pasupunuri	43,360	14.45%	50,000	16.67%
Arwa Umesh	39,900	13.30%	-	0.00%
<b>Total</b>	<b>3,00,000</b>	<b>100.00%</b>	<b>3,00,000</b>	<b>100.00%</b>



Note No. 4 RESERVES AND SURPLUS		
PARTICULARS	(All amounts are in INR in Lakhs unless otherwise stated)	
	As at March 31, 2025	As at March 31, 2024
Opening Balance	334.85	13.43
Add: Prior Period Adjustments	-	-
Add: Additions during the Year	691.09	321.42
Closing Balance	1,025.95	334.85

Note No. 5 LONG-TERM BORROWINGS		
PARTICULARS	(All amounts are in INR in Lakhs unless otherwise stated)	
	As at March 31, 2025	As at March 31, 2024
<b>Secured</b>		
Term Loans From Banks (Note 1)	440.13	682.47
<b>Unsecured</b>		
Loans and Advances from Related Parties	624.67	712.17
<b>TOTAL</b>	<b>1,064.81</b>	<b>1,394.64</b>

Note 1  
Details of Secured Loans:-  
As at 31-03-2025

PARTICULARS	Tenure of Repayment (in months)	Date of Loan	Rate of Interest (p.a.)	No of O/S Installments (in months)	Instalment Amount	Starting Date	Closing Balance as at March 31, 2025	Nature of Security
HDFC Bank Limited Car Loan	39	04-05-2022	7.32%	5	0.88	07-06-2022	4.30	Loan against Vehicle
KVB HPMA Loan A/C-1230729000004137	46	03-10-2024	9.75%	41	11.11	15-10-2024	455.56	Hypothecation of Machineris purchased out of Bank Finance
KVB Term Loan A/C-1230782000000051	36	03-10-2024	9.95%	31	2.78	15-10-2024	88.89	Fresh Equitable Mortgage Charge on Land and Building in the name of the Company
KVB Term Loan A/C-1230782000000091	84	03-10-2024	9.95%	79	1.79	22-11-2024	142.86	
<b>Total</b>							<b>691.60</b>	
Less: Current Maturities classified under Short Term Borrowings							251.47	
<b>Long Term Borrowings</b>							<b>440.13</b>	

As at 31-03-2024								
PARTICULARS	Tenure of Repayment (in months)	Date of Loan	Rate of Interest (p.a.)	No of O/S Installments (in months)	Instalment Amount	Starting Date	Closing Balance as at March 31, 2024	Nature of Security
HDFC Bank Limited Car Loan	39	04-05-2022	7.32%	15	0.88	07-06-2022	14.11	Loan against Vehicle
Indian Bank Covid Loan 2020 Ac6887665768	36	08-07-2020	7.50%	17	Floating Rate	08-07-2020	7.74	100% Coverage under GECLS
Indian Bank Covid Loan Extension 7292293070	36	13-09-2022	8.90%	17	7.08	13-09-2022	100.10	100% Coverage under GECLS and Hypothecation of Stocks and Book debts
Indian Bank Term Loan A/C 06631843032	120	09-05-2018	11.90%	60	11.36	09-05-2018	560.52	Machinery to be purchased out of Bank Finance
<b>Long Term Borrowings</b>							<b>682.57</b>	

Notes:  
(i) The figures disclosed above are based on the Financial Statements of the Company  
(ii) The rate of interest given above are as agreed with the lenders in the respective facility letters.  
(iii) The current maturities of long-term borrowings from above Note No. is included in short term borrowings

Note No. 6 LONG-TERM PROVISIONS		
PARTICULARS	(All amounts are in INR in Lakhs unless otherwise stated)	
	As at March 31, 2025	As at March 31, 2024
Provision for Employee Benefits - Gratuity	57.16	-
<b>TOTAL</b>	<b>57.16</b>	<b>-</b>



Note No. 7

SHORT-TERM BORROWINGS

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	As at March 31, 2025	As at March 31, 2024
<b>Secured</b>		
Current Maturities of Long Term Borrowings	251.47	-
Bank Overdraft and Cash Credit	558.28	442.11
<b>TOTAL</b>	<b>809.75</b>	<b>442.11</b>

Nature of Facility	Name of Institution/Banks	As at March 31, 2025	As at March 31, 2024	Nature of Security
Cash Credit	Indian Bank	(14.80)*	442.11	<b>Primary Security for Cash Credit Limit:</b> 1. Stocks and Bank Debts 2. Property Details <b>A.</b> Cad No 9/2/2/2, as per Deed, R.S. No. 4/3, Cad No. 9/2/2/1, as per Survey Settlement, Patta No. 776 1614 sq.ft. or 1 Ares 50 Centiares (Western portion on the northern side) East West on the Northern side 19.60 mts, on the Southern Side 23.40 mts. South North on the Eastern Side 6.10 mts, on the Western side 6.60 mts. Puducherry R.D., Villianur Sub- R.D., Villianur Commune Panchayat, No. 33, Kurumbapet Revenue Village, Puducherry. <b>B.</b> Cad No.9/2/2/2, as per Deed, R.S. No. 4/3, Cad No. 9/2/2/1, as per Survey Settlement, Patta No. 776. 17,216 sq.ft. or 16 Ares (Eastern portion land) East-West on the Northern Side 56.80mts. on the Southern Side 53.80 mts. South North on the Eastern side 29.80 mts, on the Western Side 27.00 mts. Puducherry R.D., Villianur Sub- R.D., Villianur Commune Panchayat, No. 33. Kurumbapet
Cash Credit	Karur Vyasa Bank	558.28	-	<b>Primary Security for Cash Credit Limit:</b> 1. Hypothecation of Entire current assets of the company including Present and future receivables. <b>Primary security for Secured Term Loans &amp; Collateral security for OCC:</b> 1. Fresh EM charge on Industrial Land and Building situated, as per French Document, Cad No 9/2/2/2, Baimash No.53, As per settlement R.S No 4/3, cad No.9/2/2/1 (As per document: Cad No.9/2/2/2), Patta No 307, Plot No 33, Kurumbapet industrial Estate, Villianur commune, Kurumbapet village No 33, Villianur, Puducherry 605009 standing in the name of M/s Sai Primus Lifebiotech Private Limited admeasuring 18830 sq ft valued Rs 12.05 Cr as per valuation report dated 19.07.2024

\* The Indian bank Cash Credit account transitioned to a positive credit balance during the Financial Year 2024-25 and has therefore been presented under Cash and Cash Equivalents.

**Notes:**  
 The Indian Bank Cash Credit Loan and the Karur Vyasa Bank Cash Credit Loan have been guaranteed by the following Directors:

- Mr E Srinivasan S/o Elangoan
- Mr Ajay babu Narayanam S/o VM Narayanam
- Mr Gangashettywar srinivas S/o Ramkrishna Gangashettywar
- Mrs J Seedevi W/o Nagendra Prasad
- Mrs Swapna P W/o Pasupunuri Rakesh

Note No. 8  
 TRADE PAYABLES

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	As at March 31, 2025	As at March 31, 2024
(A) Total Outstanding dues of Micro, Small and Medium Enterprises	-	-
(B) Total Outstanding dues of Creditors Other than Micro, Small and Medium Enterprises	2,374.81	1,306.42
<b>TOTAL</b>	<b>2,374.81</b>	<b>1,306.42</b>

Trade Payables ageing schedule As at March 31, 2025

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	Outstanding for following periods from due date of payment				Total
	< 1 Year	1 - 2 Years	2 - 3 Years	> 3 Years	
(A) Total Outstanding dues of Micro, Small and Medium Enterprises	-	-	-	-	-
(B) Total Outstanding dues of Creditors Other than Micro, Small and Medium Enterprises	2,351.82	22.99	-	-	2,374.81
(C) Disputed dues of Micro, Small and Medium Enterprises	-	-	-	-	-
(D) Disputed dues of Creditors Other than Micro, Small and Medium Enterprises	-	-	-	-	-
<b>TOTAL</b>	<b>2,351.82</b>	<b>22.99</b>			<b>2,374.81</b>



## Trade Payables ageing schedule As at March 31, 2024

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	Outstanding for following periods from due date of payment				Total
	< 1 Year	1 - 2 Years	2 - 3 Years	> 3 Years	
(A) Total Outstanding dues of Micro, Small and Medium Enterprises	-	-	-	-	-
(B) Total Outstanding dues of Creditors Other than Micro, Small and Medium Enterprises	1,306.42	-	-	-	1,306.42
(C) Disputed dues of Micro, Small and Medium Enterprises	-	-	-	-	-
(D) Disputed dues of Creditors Other than Micro, Small and Medium Enterprises	-	-	-	-	-
<b>TOTAL</b>	<b>1,306.42</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,306.42</b>

## Note No. 9

## OTHER CURRENT LIABILITIES

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	As at March 31, 2025	As at March 31, 2024
Audit Fees Payable	0.90	1.00
Employee Benefits Payable	59.05	46.43
Electricity Charges Payable	13.89	11.90
Credit Card Payable	4.39	-
Interest Payable	5.70	-
Advance from Customers	1,035.37	40.59
<b>Statutory Dues Payable</b>		
TDS Payable	18.69	14.20
GST Payable	-	-
ESI Payable	0.59	0.52
Provident Fund Payable	4.39	2.59
<b>TOTAL</b>	<b>1,142.97</b>	<b>112.23</b>

## Note No. 10

## SHORT-TERM PROVISIONS

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	As at March 31, 2025	As at March 31, 2024
Provision for Income Tax	154.18	84.47
<b>TOTAL</b>	<b>154.18</b>	<b>84.47</b>



**SAI PRIMUS LIFEBIOTECH PRIVATE LIMITED**  
R.S.No.4/3, Plot No.33, Kurumbapet, Paducherry, India, 605009  
CIN : U24304PY2017PTC008147

**Notes to the Financial Statements**

Note No. 11(a)

**PROPERTY, PLANT AND EQUIPMENT AND INTANGIBLE ASSETS**

As at 31/03/2025

*(All amounts are in INR in Lakhs unless otherwise stated)*

PARTICULARS	Gross Block				Accumulated Depreciation			Net Block		
	April 01, 2024	Additions for the year	Deletions for the year	March 31, 2025	April 01, 2024	Depreciation for the Year	Disposals	March 31, 2025	March 31, 2025	March 31, 2025
<b>Property, Plant and Equipment</b>										
Land	88.45	-	-	88.45	-	-	-	-	88.45	88.45
Building	401.92	-	-	401.92	58.17	12.74	-	70.91	331.01	343.75
Furniture & Fixtures	21.46	16.19	-	37.65	6.18	3.18	-	9.36	28.29	15.28
Office equipment	24.84	10.03	-	34.87	15.53	4.67	-	20.20	14.67	9.31
Plant & Machinery	1,352.99	73.80	-	1,426.79	356.52	86.98	-	443.50	983.29	996.47
Vehicles	47.66	-	-	47.66	12.71	7.94	-	20.65	27.01	34.95
<b>Total</b>	<b>1,937.32</b>	<b>100.03</b>	<b>-</b>	<b>2,037.33</b>	<b>549.11</b>	<b>115.52</b>	<b>-</b>	<b>564.63</b>	<b>1,472.72</b>	<b>1,488.21</b>

As at 31/03/2024

*(All amounts are in INR in Lakhs unless otherwise stated)*

PARTICULARS	Gross Block				Accumulated Depreciation			Net Block		
	April 01, 2023	Additions for the year	Deletions for the year	March 31, 2024	April 01, 2023	Depreciation for the Year	Disposals	March 31, 2024	March 31, 2024	March 31, 2023
<b>Property, Plant and Equipment</b>										
Land	88.45	-	-	88.45	-	-	-	-	88.45	88.45
Building	401.92	-	-	401.92	44.46	13.71	-	58.17	343.75	337.46
Furniture & Fixtures	13.91	7.55	-	21.46	4.28	1.92	-	6.18	15.28	9.65
Office equipment	20.43	4.41	-	24.84	10.07	5.46	-	15.53	9.31	10.36
Plant & Machinery	1,271.49	81.50	-	1,352.99	264.14	92.38	-	356.52	996.47	1,007.35
Vehicles	42.23	5.43	-	47.66	7.63	5.08	-	12.71	34.95	34.60
<b>TOTAL</b>	<b>1,639.43</b>	<b>98.89</b>	<b>-</b>	<b>1,737.32</b>	<b>330.56</b>	<b>118.53</b>	<b>-</b>	<b>439.11</b>	<b>1,458.21</b>	<b>1,507.87</b>

Note No. 11(b)

**INTANGIBLE ASSETS**

As at 31/03/2025

*(All amounts are in INR in Lakhs unless otherwise stated)*

PARTICULARS	Gross Block				Accumulated Depreciation			Net Block		
	April 01, 2024	Additions for the year	Deletions for the year	March 31, 2025	April 01, 2024	Depreciation for the Year	Disposals	March 31, 2025	March 31, 2025	March 31, 2024
Computer Software	-	24.25	-	24.25	-	3.28	-	3.28	20.97	-
<b>TOTAL</b>	<b>-</b>	<b>24.25</b>	<b>-</b>	<b>24.25</b>	<b>-</b>	<b>3.28</b>	<b>-</b>	<b>3.28</b>	<b>20.97</b>	<b>-</b>

As at 31/03/2024

*(All amounts are in INR in Lakhs unless otherwise stated)*

PARTICULARS	Gross Block				Accumulated Depreciation			Net Block		
	April 01, 2023	Additions for the year	Deletions for the year	March 31, 2024	April 01, 2023	Depreciation for the Year	Disposals	March 31, 2024	March 31, 2024	March 31, 2023
Nil	-	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>



Note No. 11(c) CAPITAL WORK IN PROGRESS			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025	As at March 31, 2024		
Opening Balance	-	-		
Add: Additions during the Year	106.80	-		
Less: Transferred/Expensed off during the year	-	-		
Closing Balance	106.80	-		

AGEING SCHEDULE FOR CAPITAL WORK IN PROGRESS AS AT 31ST MARCH 2025						(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	Ageing in CWP for a period of:				Total		
	Less than 1 year	1-2 years	2-3 years	More than 3 years		As at March 31, 2025	As at March 31, 2024
Projects in Progress	106.80	-	-	-	106.80	-	-
Projects Temporarily Suspended	-	-	-	-	-	-	-
TOTAL	106.80	-	-	-	106.80	-	-

Note No. 11(d) INTANGIBLE ASSETS UNDER DEVELOPMENT			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025	As at March 31, 2024		
Opening Balance	-	-		
Add: Additions during the Year	58.03	-		
Less: Transferred/Expensed off during the year	-	-		
Closing Balance	58.03	-		

AGEING SCHEDULE OF INTANGIBLE ASSETS UNDER DEVELOPMENT AS AT 31ST MARCH 2025						(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	Ageing in IADU for a period of:				Total		
	Less than 1 year	1-2 years	2-3 years	More than 3 years		As at March 31, 2025	As at March 31, 2024
Projects in Progress	58.03	-	-	-	58.03	-	-
Projects Temporarily Suspended	-	-	-	-	-	-	-
TOTAL	58.03	-	-	-	58.03	-	-

Note No. 12 DEFERRED TAX ASSET			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025	As at March 31, 2024		
Deferred Tax Asset	-	-		
On Account of Depreciation	(127.67)	11.81		
On Account of Gratuity	15.90	-		
TOTAL	(111.77)	11.81		

Note No. 13 LONG-TERM LOANS AND ADVANCES			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025	As at March 31, 2024		
Other Loans and Advances	-	-		
Rental Advances	21.00	18.29		
TOTAL	21.00	18.29		

Note No. 14 OTHER NON-CURRENT ASSETS			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025	As at March 31, 2024		
Security Deposits	25.05	25.87		
TOTAL	25.05	25.87		

Note No. 15 INVENTORIES			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025	As at March 31, 2024		
Inventories	-	-		
Raw Material	1,536.10	528.05		
Packing Material	688.77	541.31		
Work In Progress	596.22	12.58		
Finished Goods	316.23	280.66		
TOTAL	3,137.32	1,362.61		



Note No. 16 TRADE RECEIVABLES			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025		As at March 31, 2024	
Undisputed Trade Receivable Considered Good	1,080.62		555.61	
Undisputed Trade Receivable Considered Doubtful	-		-	
Disputed Trade Receivable Considered Good	-		-	
Disputed Trade Receivable Considered Doubtful	-		-	
Less: Bad debts provision	-		-	
<b>TOTAL</b>	<b>1,080.62</b>		<b>555.61</b>	

Trade Receivables ageing schedule As at March 31, 2025							(All amounts are in INR in Lakhs unless otherwise stated)
PARTICULARS	Outstanding for following periods from due date of payment					Total	
	< 6 Months	6 Months - 1 Year	1 - 2 Years	2 - 3 Years	> 3 Years		
Undisputed Trade Receivable Considered Good	1,079.16	-	21.46	-	-	1,080.62	
Undisputed Trade Receivable Considered Doubtful	-	-	-	-	-	-	
Disputed Trade Receivable Considered Good	-	-	-	-	-	-	
Disputed Trade Receivable Considered Doubtful	-	-	-	-	-	-	
Less: Bad debts provision	-	-	-	-	-	-	
<b>TOTAL</b>	<b>1,079.16</b>		<b>21.46</b>			<b>1,080.62</b>	

Trade Receivables ageing schedule As at March 31, 2024							(All amounts are in INR in Lakhs unless otherwise stated)
PARTICULARS	Outstanding for following periods from due date of payment					Total	
	< 6 Months	6 Months - 1 Year	1 - 2 Years	2 - 3 Years	> 3 Years		
Undisputed Trade Receivable Considered Good	555.61	-	-	-	-	555.61	
Undisputed Trade Receivable Considered Doubtful	-	-	-	-	-	-	
Disputed Trade Receivable Considered Good	-	-	-	-	-	-	
Disputed Trade Receivable Considered Doubtful	-	-	-	-	-	-	
Less: Bad debts provision	-	-	-	-	-	-	
<b>TOTAL</b>	<b>555.61</b>					<b>555.61</b>	

Note No. 17 CASH AND CASH EQUIVALENTS			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025		As at March 31, 2024	
Cash & Cash Equivalents				
i) Balance with Banks		14.98		0.18
ii) Cash on Hand		0.59		0.11
Other Bank Balances				
Bank Deposits with less than twelve months maturity		5.15		15.00
<b>TOTAL</b>		<b>20.72</b>		<b>25.29</b>

Note No. 18 SHORT TERM LOANS AND ADVANCES			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025		As at March 31, 2024	
Advance - Suppliers	433.00		81.89	
Advance - Employees	10.72		12.43	
<b>TOTAL</b>	<b>443.72</b>		<b>94.32</b>	

Note No. 19 OTHER CURRENT ASSETS			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	As at March 31, 2025		As at March 31, 2024	
Balance with Revenue Authorities	56.17		33.96	
GST Input Tax Credit	327.25		103.83	
<b>TOTAL</b>	<b>383.42</b>		<b>137.79</b>	

Note No. 20 REVENUE FROM OPERATIONS			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	For the year ended			
	March 31, 2025	March 31, 2024		
Sale of Products				
(a) Domestic Operations	6,502.53		5,611.12	
(b) International Operations	1,395.27		76.94	
<b>TOTAL</b>	<b>7,897.80</b>		<b>5,688.06</b>	

Note No. 21 OTHER INCOME			(All amounts are in INR in Lakhs unless otherwise stated)	
PARTICULARS	For the year ended			
	March 31, 2025	March 31, 2024		
Interest Income	0.04		0.72	
Other Non-operating Income (Refer Note below)	44.33		14.34	
<b>TOTAL</b>	<b>44.37</b>		<b>15.06</b>	



Note: Other Non-operating Income		
(All amounts are in INR in Lakhs unless otherwise stated)		
PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Other Non-operating Income:</b>		
Discount received	3.24	4.46
Liability written back	-	7.21
Other Income	-	2.68
Subsidy received	30.25	-
Foreign Exchange Fluctuation Gain	10.73	-
<b>TOTAL</b>	<b>44.55</b>	<b>14.34</b>

Note No. 22		
DIRECT OPERATING EXPENSES		
(All amounts are in INR in Lakhs unless otherwise stated)		
PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Purchase of Raw Materials and Consumables</b>		
Purchase of Raw Materials	6,042.11	3,166.52
Add: Opening Inventories	1,362.60	1,109.60
Less: Closing Inventory	(3,137.32)	(1,862.60)
<b>Sub Total (A)</b>	<b>4,267.39</b>	<b>3,213.52</b>
<b>Direct Expenses</b>		
Packing Material Charges	0.05	-
Freight Charges	245.07	36.18
Loading and Unloading Charges	1.06	2.56
Lab Testing Charges	4.17	0.73
<b>Sub Total (B)</b>	<b>250.35</b>	<b>39.47</b>
<b>TOTAL (A+ B)</b>	<b>4,517.73</b>	<b>3,253.00</b>

Note No. 23		
EMPLOYEE BENEFIT EXPENSES		
(All amounts are in INR in Lakhs unless otherwise stated)		
PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Salaries & Wages (Refer Note below)	1,129.82	883.58
Contribution to Provident and Other funds	21.24	13.73
Gratuity Expenses	57.16	-
Employee State Insurance	5.54	4.60
Incentive	94.33	70.03
Staff Welfare	55.08	36.29
Professional Tax	0.33	0.65
<b>TOTAL</b>	<b>1,363.50</b>	<b>1,009.98</b>

NOTE : SALARIES & WAGES		
PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Salary	849.02	681.08
Director's Remuneration	280.80	202.50
<b>TOTAL</b>	<b>1,129.82</b>	<b>883.58</b>

Note No. 24		
FINANCE COSTS		
(All amounts are in INR in Lakhs unless otherwise stated)		
PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest Expenses	130.65	120.59
Other Borrowing Costs	17.02	3.66
<b>TOTAL</b>	<b>147.67</b>	<b>124.24</b>

Note No. 25		
DEPRECIATION & AMORTISATION EXPENSES		
(All amounts are in INR in Lakhs unless otherwise stated)		
PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Depreciation and Amortisation	118.80	118.55
<b>TOTAL</b>	<b>118.80</b>	<b>118.55</b>



Note No. 26

OTHER EXPENSES

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Payment to Auditors (Refer Note below)	1.00	1.00
Business Promotion Expenses	10.14	-
Legal Expenses	0.14	0.70
Security Services	8.17	7.29
Transportation Charges	47.89	70.17
Printing & Stationery	30.07	25.71
Rates & Taxes	19.11	45.90
Advertisement	0.23	0.38
Donation	-	1.00
Art Work Charges	1.52	1.46
Customs Clearing Charges	-	0.92
Miscellaneous Expenses	31.47	6.30
Service Charges	0.59	2.31
Power & Fuel	174.60	170.86
Rental Expenses	41.81	33.24
Travelling & Conveyance	65.99	86.29
Insurance	3.99	6.22
Professional and Consultancy Charges	51.51	45.16
New Product Development Registration Fees	3.12	-
Software Expenses	0.18	-
Communication Charges	9.00	5.99
Books, Periodicals, Subscriptions and Memberships	1.25	1.36
Bad Debts Written off	13.29	-
Repairs & Maintenance	141.64	115.81
Pooja Fees	7.41	4.40
Commission	55.70	19.82
Foreign exchange fluctuation Loss	-	-
Late Fees & Penalty	3.80	1.03
<b>TOTAL</b>	<b>737.63</b>	<b>663.97</b>

NOTE: PAYMENT TO AUDITORS

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
a. Statutory Audit Fees	0.75	0.75
b. Tax Audit Fees	0.25	0.25
c. Others Services	-	-
<b>TOTAL</b>	<b>1.00</b>	<b>1.00</b>

Note No. 27

EARNINGS PER SHARE

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
PAT as per P&L Account for Basic EPS	691.09	321.42
PAT as per P&L Account for Diluted EPS	691.09	321.42
Basic EPS	230.36	107.14
Weighted Average Number of Equity Shares at the end of the Year / Period	3,00,000	3,00,000
Diluted EPS	230.36	107.14
Weighted Average Number of Equity Shares at the end of the Year / Period	3,00,000	3,00,000
Net Worth	1,055.95	364.85
Current Assets	5,065.81	2,165.60
Current Liabilities	4,481.70	1,950.24
EBITDA	1,293.31	736.83
Earnings Per Share		
Basic (Rs.)	230.36	107.14
Diluted (Rs.)	230.36	107.14
Net Asset Value Per Equity Share (Rs.)	351.98	121.62
Return on Net Worth (%)	65.45%	88.10%
Current Ratio	1.13	1.11

Ratios have been calculated as below

Basic and Diluted Earnings Per Share (EPS) (Rs.)

$$\frac{\text{Profit after Tax available to equity Shareholders}}{\text{Weighted Average Number of Equity Shares at the end of the year / period}}$$

Return on Net Worth (%)

$$\frac{\text{Profit after Tax available to equity Shareholders}}{\text{Net Worth of Equity Shareholders}}$$

Net Asset Value per equity share (Rs.)

$$\frac{\text{Net Worth of Equity Shareholders}}{\text{Number of Equity Shares outstanding at the end of the year / period}}$$



**Note No. 28**  
**LIST OF RELATED PARTIES**

S.No.	Name of the Party	Nature of Related Party	Relationship
1	Srinivasan	Managing Director	Managing Director
2	Ajay Babu Narayanam	Director	Director
3	Srinivas Gangashettywar	Director	Director
4	Venkata Nagendraprasad Jonnalagadda	Director	Director
5	Sridevi Jonnalagadda	Director	Director
6	Swapna Pasupunuri	Director	Director
7	Rakesh Pasupunuri	Director	Director
8	Primus Remedies Private Limited	Company which is having Common Directors	Company controlled and influenced by directors
9	Lifecare Formulations Private Limited	Company which is having a Common Director	Company controlled and influenced by directors

**TRANSACTION WITH RELATED PARTIES DURING THE YEAR**

(All amounts are in INR in Lakhs unless otherwise stated)

Name of the Related Party	Nature of Transaction	FY 2024-25		FY 2023-2024	
		Transactions During the Year	Amount	Transactions During the Year	Amount
			(Receivable)/Payable as at March 31, 2025		(Receivable)/Payable as at March 31, 2024
SRINIVASAN	Unsecured Loan Given	-	138.55	-	156.05
	Repayment of loan given	17.50	-	-	-
	Remuneration Paid	66.00	4.00	64.00	2.50
AJAY BABU NARAYANAM	Unsecured Loan Given	-	121.62	-	139.12
	Repayment of loan given	17.50	-	-	-
	Remuneration Paid	53.70	3.50	40.50	2.50
SRINIVAS GANGASHETTYWAR	Unsecured Loan Given	-	121.50	-	139.00
	Repayment of loan given	17.50	-	-	-
	Remuneration Paid	53.70	3.50	40.50	2.50
VENKATA NAGENDRAPRASAD JONNALAGADDA	Unsecured Loan Given	-	-	-	-
	Repayment of loan given	-	-	-	-
	Remuneration Paid	24.00	3.50	-	-
SRIDEVI JONNALAGADDA	Unsecured Loan Given	-	121.50	-	139.00
	Repayment of loan given	17.50	-	-	-
	Remuneration Paid	29.70	-	40.50	2.50
SWAPNA PASUPUNURI	Unsecured Loan Given	-	121.50	-	139.00
	Repayment of loan given	17.50	-	-	-
	Remuneration Paid	29.70	-	40.50	2.50
RAKESH PASUPUNURI	Unsecured Loan Given	-	-	-	-
	Repayment of loan given	-	-	-	-
	Remuneration Paid	24.00	3.50	-	-
PRIMUS REMEDIES PRIVATE LIMITED	Sales	1,432.65	(91.62)	1,448.00	(102.27)
LIFECARE FORMULATIONS PRIVATE LIMITED	Trade Advance Given	46.55	-	30.68	-
	Repayment of Trade Advance given	58.78	(28.69)	23.74	(20.92)

**Note No. 29**  
**PROVISION FOR GRATUITY**

**Gratuity** - The Present value of obligation is determined based on actuarial valuation using the Projected Unit Credit Method. This method considers each period of service as giving rise to an additional unit of benefit entitlement and measures each unit separately to build up the final obligation.

**Interest cost** - It is the increase in the Plan liability over the accounting period resulting from the operation of the actuarial assumption of the interest rate.

**Current Service Cost** - is the discounted present value of the benefits from the Plan's benefit formula attributable to the services rendered by employees during the accounting period.

**Actuarial Gain or Loss** - occurs when the experience of the Plan differs from that anticipated from the actuarial assumptions. It could also occur due to changes made in the actuarial assumptions.

**(i) RECONCILIATION OF OPENING AND CLOSING BALANCE OF GRATUITY OBLIGATIONS:**

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Net Liability as at the Beginning of the Period	-	-
Net Expenses in P/L A/c	57.16	-
Benefits Paid	-	-
Net Liability as at the End of the Period	57.16	-
Present Value of Gratuity Obligation (Closing)	57.16	-

**(ii) EXPENSES RECOGNISED IN STATEMENT OF PROFIT AND LOSS DURING THE YEAR:**

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest Cost	3.03	-
Current Service Cost	29.34	-
Past Service Cost	8.92	-
Expected Return on Plan Assets	-	-
Curtailment Cost (Credit)	-	-
Settlement Cost (Credit)	-	-
Net Actuarial (gain) / loss	15.87	-
Net Expenses to be recognized in P/L	57.16	-
<b>TOTAL</b>	<b>57.16</b>	<b>-</b>

**(iii) CHANGES IN BENEFIT OBLIGATIONS:**

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
Opening Defined benefit Obligation	-	-
Current Service Cost	29.34	-
Interest Cost for the Year	3.03	-
Past Service Cost	8.92	-
Actuarial losses (gains)	15.87	-
Benefits Paid	-	-
Closing Defined Benefit Obligation	57.16	-
<b>TOTAL</b>	<b>57.16</b>	<b>-</b>



**(iv) ACTUARIAL ASSUMPTIONS:**

PARTICULARS	For the year ended	For the year ended
	March 31, 2025	March 31, 2024
Rate of Discounting	6.88%	-
Salary Escalation	7.00%	-
Attrition Rate	10.00%	-
Mortality rate during employment Indian	Indian Assured Lives Mortality (2012-14) Ultimate	-

\*The estimates of rate of escalation in salary considered in actuarial valuation, take into account inflation, seniority, promotion and other relevant factors including supply and demand in the employment market. The above information is certified by the actuary.

**Note No. 30****CONTINGENT LIABILITY***(All amounts are in INR in Lakhs unless otherwise stated)*

PARTICULARS	For the year ended	For the year ended
	March 31, 2025	March 31, 2024
Claims against the Company not Acknowledged as Debt		-
(a) TDS demand	-	-
(b) Income Tax demand	-	-
(c) GST	-	-
Other money for which the Company is Contingently liable		-
<b>TOTAL</b>		



**SAI PRIMUS LIFE BIOTECH PRIVATE LIMITED**  
R.S.No.4/3, Plot No.33, Kurumbapet, Puducherry, India, 605009  
CIN : U24304PY2017PTC008147

**Notes to the Financial Statements**

**Note No. 31**

**Financial Ratios**

*(All amounts are in INR in Lakhs unless otherwise stated)*

Particulars	As at March 31, 2025			As at March 31, 2024		
	Numerator	Denominator	Ratio	Numerator	Denominator	Ratio
Current Ratio (in times) Current Assets / Current liabilities	5,065.81	4,481.70	1.13	2,165.60	1,950.24	1.11
Debt-Equity Ratio (in times) Total Outside Liabilities / Total Shareholder's Equity	1,874.56	1,055.95	1.78	1,836.75	364.85	5.03
Debt Service Coverage Ratio (in times) EBITDA / (Interest + Principal)	1,233.31	2,022.23	0.61	736.83	1,960.99	0.38
Return on Equity Ratio (in times) (Net Profit After Taxes - Preference Dividend if any) / Average Shareholders	691.09	710.40	0.97	321.42	198.20	1.62
Trade Receivables Turnover Ratio Credit Sales / Average Trade Receivables	7,897.80	818.11	9.65	5,638.06	683.99	8.24
Inventory Turnover Ratio (in times) COGS or sales / Average Inventory	7,897.80	2,249.96	3.51	5,638.06	1,236.10	4.56
Trade payable Turnover Ratio (in times) Credit purchases/ Average Trade Payables	6,042.11	1,840.61	3.28	3,466.52	1,625.29	2.13
Net Capital Turnover Ratio (in times) Cost of Goods Sold (or) Sales / Average working capital	7,897.80	399.74	19.76	5,638.06	88.41	63.77
Net Profit Ratio (in %) Net Profit / Total Sales	691.09	7,897.80	0.09	321.42	5,638.06	0.06
Return on Capital Employed (in %) (EBIT / Capital Employed) * 100	1,114.51	2,930.50	0.38	618.28	2,201.60	0.28
Return On investment (in %) (Income generated from investment funds / Total Investment)	NA	NA	NA	NA	NA	NA



**ADDITIONAL DISCLOSURES WITH RESPECT TO AMENDMENTS TO SCHEDULE III**

- (i) The Company have no immovable property whose title deeds are not held in the name of the company.  
 (ii) The Company has not revalued its Property, Plant and Equipment during the reporting years.  
 (iii) Loans and Advances granted to Promoters, Directors, KMP and Related Parties:  
 There are no Loans and Advances in the nature of loans that are granted to promoters, directors, KMP's and the related parties either severally or jointly with any other person, that are repayable on demand.  
 (iv) There are no proceedings initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988).  
 (v) The Company has Capital Work in progress as at the end of the balance sheet dated 31-03-2025. The Capital WIP includes payment made for Furniture and Fixtures, Office Equipment and Plant and Machinery for which operations are yet to commence. Therefore identified as not yet ready for their intended use as at the date of the Balance Sheet.  
 (vi) The Company has Intangible Assets under development comprising of Foreign Trade Expenses, as at the end of the Balance Sheet dated 31st March 2025.  
 (vii) The Company has made borrowing from the banks or financial institutions on the basis of security of current assets, and the statements of current assets as required to be filed by the Company with any banks or financial institutions are done periodically.  
 (viii) The Company is not declared as willful defaulter by any bank or financial institution or other lender.  
 (ix) The Company has not entered into any transactions with companies struck off under section 248 of the Companies Act, 2013.  
 (x) The Company has no subsidiaries with one layer prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017.  
 (xi) No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.  
 (x) Utilisation of Borrowed funds and share premium:  
 A. The Company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:  
 (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or  
 (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.  
 B. The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:  
 (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or  
 (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

**INFORMATION REGARDING MATERIAL CONSUMPTION AND IMPORTS**

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Raw Materials Consumed-Imported/Indigenous:</b>		
Imported:		
Value	11.32	1.19
% to total consumption	0.19%	0.03%
Indigenous:		
Value	6,030.79	3,465.33
% to total consumption	99.81%	99.97%
<b>Total</b>	<b>6,042.11</b>	<b>3,466.52</b>
<b>Value of imports on CIF Basis:</b>		
Raw materials	11.32	1.19
Stores and spares	-	-
Capital goods	-	-
<b>TOTAL</b>	<b>11.32</b>	<b>1.19</b>

**EARNINGS IN FOREIGN CURRENCY**

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	For the year ended	For the year ended
Export Sales	1,355.27	26.94
<b>TOTAL</b>	<b>1,355.27</b>	<b>26.94</b>

**EXPENDITURE IN FOREIGN CURRENCY**

(All amounts are in INR in Lakhs unless otherwise stated)

PARTICULARS	As at March 31, 2025	As at March 31, 2024
New Product Development Registration Charges	58.03	-
<b>TOTAL</b>	<b>58.03</b>	<b>-</b>

**Disclosure on applicability of Segment Reporting**

As the company's operations are not divided into different business segments or various geographical locations, so the disclosure requirement as per AS 17 are not applicable and no segment information is provided.

